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ABSTRACT 
 
 
The blood brain barrier is the body’s natural defense system for limiting the brain’s 
exposure to potentially harmful xenobiotics.  This barrier exists between the blood of the 
systemic circulation and the brain and is made up of brain endothelial cells which have 
tight junctions, reduced pinocytosis, minimal fenestration and increased expression of 
metabolizing enzymes and membrane transporters capable of efflux.  Estimates predict 
that the blood brain barrier may be capable of limiting up to 98% of all drugs from 
entering the brain and is therefore a major obstacle in drug delivery.  The research 
presented herein highlights several small molecules that possess chemotherapeutic and 
neuroprotective properties.  These molecules also represent various strategies for 
improving blood brain barrier penetration.  Derivatives of the microtubule stabilizing 
agent paclitaxel were investigated in which chemical modification was employed to 
reduce interaction with the efflux transporter P-glycoprotein, which is critical in limiting 
paclitaxel’s entry into the brain.  TH-237A, another microtubule stabilizing agent that is 
structurally very different from paclitaxel was also characterized and was shown to have 
excellent blood brain barrier penetration.  Additionally, derivatives of the monoamine 
oxidase inhibitor tranylcypromine were explored that have fatty acid and lipoamino acid 
chains of varying length attached to improve blood brain barrier permeability.  In order 
for these compounds to exert their mechanism of action as either chemotherapeutic or 
neuroprotective agents, they must be able to penetrate the blood brain barrier.  The 
specific objective of this project was to explore various chemical approaches to 
improving blood brain barrier permeability using pharmacologically relevant molecules. 
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1.  Introduction 
 
The delivery of pharmaceutical agents to the brain remains one of the greatest challenges 
in drug delivery.  The central nervous system has evolved many biological mechanisms 
to protect the brain from circulating toxins, including the blood brain barrier.  This 
protective barrier is formed by the brain capillary endothelial cells that are characterized 
by tight junctions, reduced pinocytosis and minimal fenestration (Reese and Karnovsky, 
1967; Brightman and Reese, 1969).  Additionally, these brain endothelial cells have 
increased expression of transport proteins capable of drug efflux (Hegmann et al., 1992; 
Tatsuta et al., 1992; Huai-Yun et al., 1998) as well as metabolizing enzymes (Spatz and 
Mrsula, 1982).  In order for drugs to reach specific targets within the brain for treatment 
of diseases such as cancer, Alzheimer’s, etc. the molecules must be able to circumvent 
these barriers.  Current strategies for delivery of drugs to the brain vary and each has its 
own individual successes and failures.     
 
1.1 Strategies for drug delivery to the brain 
 
A variety of delivery strategies exist for achieving drug exposure within the central 
nervous system, and many of these have arisen from a need for successful treatment 
options for patients with primary and metastatic brain tumors.  Current strategies include, 
but are not limited to, osmotic and chemical disruption of the blood brain barrier, direct 
injection or infusion into the brain, concurrent administration of drug efflux inhibitors, 
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targeting of endogenous uptake transporters expressed at the brain endothelium, and 
chemical modification of existing pharmacologic agents (Groothuis, 2000).   
 
The idea of transient disruption of the blood brain barrier has been around for some time, 
first proposed by Rapoport et al. in the 1970’s (Rapoport and Thompson, 1973).  This 
method involves the infusion of a hyperosmolar solution, usually mannitol, into a 
cerebral artery resulting in a transient increase in permeability due to osmotic shrinkage 
of the endothelial cells.  The use of pharmacologic agents as transient disruptors has also 
been explored.  Lobradimil (Cereport, RMP-7) is a bradykinin analog that has been 
clinically tested as a CNS enhancing agent (Bartus et al., 1996).  Interestingly, it was 
found that the disruption caused by lobradimil was more pronounced in brain-tumor 
vasculature than in normal brain tissue which could be beneficial in the treatment of 
primary and metastatic brain tumors.  This method of delivery, however, has obvious 
disadvantages, including its invasive nature as well as its transient effect.  Furthermore, 
during this disruption, the BBB is not able to preserve the delicate homeostasis it has 
been designed to maintain, and this can potentially result in a host of complications. 
 
Direct injection or infusion is one of the less elegant, but nevertheless effective methods 
of drug delivery into the brain.  In this case, the blood brain barrier is bypassed 
completely and close to 100% of the administered dose can be delivered.  Administration 
can be intrathecal, intratumoral, or intraventricular, but the principal disadvantages are 
the same- unpredictable distribution relying solely on diffusion, highly invasive nature, 
and risk for neurotoxicity in healthy tissue (Groothuis, 2000).  Recently, the technique of 
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convection-enhanced therapy (CED) has been developed in an attempt to overcome the 
diffusion problem (Morrison et al., 1999; Croteau et al., 2005).  This is a technique in 
which the therapeutic agent is pumped into the target tissue with a pressure differential.  
Although some efficacy has been observed in preclinical trials (Kaiser et al., 2000; 
Degen et al., 2003), the potential for success in humans has yet to be seen.     
 
Exclusion of drugs caused by efflux proteins (eg: P-gp, MRP, BCRP) expressed at the 
blood brain barrier presents an additional challenge, and inhibition of these protein 
systems has been explored (Nobili et al., 2006; O'Connor, 2007).  Clinical trials of 
molecules designed to inhibit P-glycoprotein are ongoing and include inhibitors such as 
cyclosporine A and PSC833 (Sikic et al., 1997).  To date the results have not been too 
promising and the failure is most likely due to their nonspecific affinity to the efflux 
protein as well as the redundant mechanisms of exclusion that exist at the BBB.  The risk 
of drug-drug interactions is also a concern with the use of these inhibitors and could have 
major effects on pharmacokinetics and toxicity of the parent compound. 
 
Targeting of endogenous uptake transporters expressed at the brain endothelium has not 
been commonly pursued, but has been explored in other fields with some success.  The 
intestinal permeation of the antiviral drug acyclovir was enhanced by attaching a valine 
moiety to the drug.  The new prodrug, valacyclovir, had increased permeability due to its 
recognition by an endogenous peptide transporter (de Vrueh et al., 1998).  Interestingly 
enough, it was not due to recognition by an amino acid transporter as might have been 
expected.  This strategy, while more commonly seen when attempting to improve 
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intestinal permeability may be a feasible strategy in improving delivery across the BBB.  
Sakaeda et al. showed that the blood brain barrier permeability of an analogue of the 
antitumor agent D-Mephalan, could be increased by conjugation with L-glutamate 
(Sakaeda et al., 2000).   Additionally, Walker et al. showed that the permeability of the 
antiviral agent phosphonoformate could be improved across porcine brain microvessel 
endothelial cells following conjugation with L-Tyrosine (Walker et al., 1994).  Capillary 
endothelial cells are known to express carriers for the uptake of essential substances such 
as amino acids, monocarboxylic acids, amines and biotin (Pardridge and Oldendorf, 
1977; Pardridge, 1986).  Studies investigating the attachment of nutrient groups including 
succinate and biotin derivatives in an attempt to improve blood brain barrier permeability 
have been performed in our laboratory and will be discussed herein.  
 
 Chemical modification of existing drugs may be one of the best strategies for improving 
delivery across the BBB and extensive work in this area has been done in our laboratory.  
Chemical modifications that retain potency but improve the overall physicochemical 
characteristics of the molecule, or eliminate recognition elements which cause the 
molecule to be excluded by efflux proteins, may hold the most promise.  Furthermore, it 
should not be overlooked that the principle route by which most molecules cross the 
blood brain barrier is by passive diffusion.  Thus the incorporation of favorable 
physicochemical properties or discovery of new molecules with inherently good 
physicochemical properties may be the most successful approach, as was demonstrated 
with the novel small molecule agents described in Chapters 3 and 4. 
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1.2 Disease states of the central nervous system 
 
A large number of CNS diseases exist and their treatment remains a great challenge to the 
pharmaceutical industry.  Treatment is often complicated by the very restrictive nature of 
the blood brain barrier.   
 
Although the incidence of primary brain tumor is relatively low compared to other types 
of cancer, the prognosis is quite bleak.  Chemotherapeutics, such as paclitaxel, that are 
effective in combating other cancers, cannot be used to treat tumors within the CNS due 
to their inability to cross the BBB (Fellner et al., 2002).  Treatment of neurodegenerative 
diseases such as Alzheimer’s has also been hampered by an inability to achieve 
therapeutic levels of drug at the site of action (Jolliet-Riant and Tillement, 1999; Bodor 
and Buchwald, 2002).  Interestingly, research detailed in the following chapters describes 
compounds with potentially good blood brain permeability that have the unique feature of 
being both chemotherapeutic as well as neuroprotective against the β-amyloid induced 
neurodegeneration that occurs in Alzheimer’s disease.  These molecules include 
structural analogues of paclitaxel, a novel small molecule called TH-237A and a novel 
Hsp90 inhibitor, A4.  These compounds have been shown to stabilize microtubules. It is 
via this mechanism that they are purported to induce cell death in cancer cells as well as 
maintain the integrity of the cytoskeletal network which may help neurons survive the 
toxic effects of β-amyloid (Michaelis et al., 2005).  Additionally, the blood brain barrier 
permeability of TCP-FA4 is described, and this is a derivative of the monoamine oxidase 
inhibitor tranylcypromine. Although TCP-FA4 could be potentially neuroprotective it 
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does not demonstrate the dual function of being chemotherapeutic like the other 
compounds described. 
 
1.3 Techniques for studying blood brain barrier permeability 
 
A variety of techniques exist for studying the permeability of pharmaceuticals across the 
blood brain barrier. Although no one technique is perfect, these methods are invaluable 
tools for helping researchers understand the complex biology of the blood brain barrier.  
Used together these various in vitro and in situ models can be used to predict the 
likelihood of a pharmaceutical agent crossing the blood brain barrier and are, therefore, 
essential to the drug discovery process when the site of action lies within the central 
nervous system.   
 
1.3.1 Cell culture models 
 
It is widely accepted that cell culture is among the most suitable of the models used to 
predict blood brain barrier permeability.  Brain microvessel endothelial cells (BBMECs) 
grown in culture offer a brain-derived, primary cell line with many of the physiological 
characteristics of the blood brain barrier including minimal fenestra and reduced 
pinocytic vesicles (Audus and Borchardt, 1987).  Additionally, many enzymes associated 
with the blood brain barrier are expressed in the BBMEC system including alkaline 
phosphatase, angiotensin-converting enzyme and monoamine oxidase (Audus and 
Borchardt, 1987).  The existence of membrane proteins responsible for both efflux and 
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uptake of molecules has also been shown in BBMECs.  These include the efflux 
transporters P-glycoprotein (Fontaine et al., 1996) and multidrug resistance-associated 
protein (MRP) (Huai-Yun et al., 1998).  Additionally, nutrient uptake transporters have 
been characterized in BBMECs including a biotin uptake system (Shi et al., 1993) and 
evidence exists for monocarboxylic acid, dipeptide and neutral amino acid transporters 
(Audus and Borchardt, 1986).  Since the BBMECs are a primary cell line that does not 
retain their morphological features upon repeated passage, there have been attempts to 
establish an immortalized cell line.  
 
TBMECs are an immortalized cell line in which brain microvessel endothelial cells are 
transfected with a plasmid containing the middle-T antigen gene from polyoma virus 
(Yazdanian and Bormann, 2000).  They grow monolayers in culture and maintain an 
endothelial cell phenotype after repeated passages.  Although the TBMECs express 
functional P-gp, as evidenced by an increase in cellular uptake of P-gp substrates such as 
rhodamine 123 in the presence of P-gp inhibitors, they lack asymmetry in the efflux of P-
gp substrates as compared to primary BBMECs (Rice, 2002).  Therefore, their utility in 
studying efflux transporters is limited to studying cellular uptake. However, these cells 
have the advantage over primary BBMECs that it is not necessary to perform repeated 
isolations and confluent monolayers form more rapidly (7 days versus 14 days for 
primary BBMECs).   
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1.3.2 Side-bi-Side™ diffusion chambers  
 
BBMECs grown on permeable filters or filter inserts allow one to study the transport 
properties of various molecules across the cell monolayer.  Although the convenient and 
disposable Transwell® insert system can be used for BBMECs, the cells tend to not grow 
as well at the edges of the filter and this phenomenon results in a leakier monolayer as 
evidenced by increased flux of low permeability markers.  Additionally the Transwell® 
system lacks convenient temperature control and agitation of the unstirred water layer can 
be challenging.  Therefore, a Side-bi-Side™ diffusion apparatus (Crown Glass, Inc. 
Somerville, NJ) was used for the permeability studies described in the following chapters.   
This set up consists of two glass chambers surrounded by thermal jackets which are 
maintained by a circulating water bath.  BBMECs are grown on polycarbonate 
membranes (13 mm diameter, 0.4 µm pore size) which are mounted horizontally between 
the two chambers.  Chambers are filled with an aqueous buffer solution which is stirred 
by magnetic stir bars driven by and external drive console (Figure 1.1). 
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Figure 1.1 Schematic of the Side-bi-Side™ diffusion apparatus (Ho et al., 1999) 
 
 
Permeability studies are conducted by filling the donor (luminal) and receiver 
(abluminal) chambers with PBSA (phosphate buffered saline supplemented with CaCl2, 
MgSO4, glucose and L-ascorbic acid) pre-warmed to 37 degrees C. The donor side is then 
spiked with test compound at the desired concentration (typically 5-10 µM) and stirring 
of the chambers begins.  Aliquots are removed from the donor chambers at time zero to 
establish concentration and subsequently from the receiver chambers at various time 
points.  The removal of each aliquot from the receiver chamber is followed by 
replacement with blank PBSA pre-warmed to 37 degrees C, which eliminates any volume 
differences between the chambers that could affect flux.  Upon completion of the study, 
Donor  
3.0 mL 
Receiver  
  3.0 mL 
Cell layer 
Collagen layer 
Polycarbonate filter 
13 mm diameter (0.4 µm pores) 
Stir bar 
Thermostated  
water jacket 
Buffer 
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[14C]-sucrose, a low permeability paracellular marker, is added to the donor chamber in 
trace quantities and aliquots are removed from the receiver chamber at 10, 20 and 30 
minutes.  Samples are analyzed by liquid scintillation counting and the permeability of 
sucrose is calculated.  This exercise serves as a control to insure that monolayer integrity 
has not been disrupted throughout the course of the study.  A sucrose permeability of 
approximately 5 x 10-5 cm/sec is expected if the monolayer has remained intact.   
 
Modifications to this experimental setup can offer additional information.  For example, 
studies can be performed to monitor the asymmetric transport of compounds by spiking 
the receiver solution and calculating flux in the abluminal to luminal direction.  Also, the 
temperature of the chambers can be reduced to 4 degrees to determine the effects of a 
reduction in ATP activity.  Furthermore, the determination of a compound’s permeability 
at a range of temperatures can be used to generate an Arrhenius plot from which an 
activation energy of transport can be calculated. 
 
1.3.3 Rhodamine 123 uptake assay 
 
Another in vitro assay utilizing BBMECs can be used for prediction of a drug’s 
interaction with the efflux transporter P-glycoprotein.  In this cellular uptake assay, the 
fluorescent dye, rhodamine 123 is used as a surrogate P-gp substrate (Fontaine et al., 
1996).  The effect of the test compound on intracellular accumulation of rhodamine 123 
is determined by monitoring intracellular fluorescence (excitation λ: 485, emission λ: 
530). If the test compound is a substrate for P-gp, then addition of the compound will 
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increase rhodamine 123 uptake relative to the negative control.  This in vitro assay was 
used extensively for the work described in upcoming chapters in which structurally 
modified analogues of paclitaxel were screened for interaction with P-gp.  Observation 
by confocal microscopy confirms that there is minimal rhodamine 123 accumulation in 
BBMECs following incubation with a 5 µM solution of rhodamine 123.  However, in the 
presence of 10 µM paclitaxel, another known substrate for P-gp, the intracellular 
accumulation of rhodamine 123 is greatly increased and is distributed throughout the cell 
(Figure 1.2). 
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Figure 1.2.1 Rhodamine 123 accumulation in BBMECs after treatment with 5 µM 
rhodamine 123.  
 
 
Figure 1.2.2 Rhodamine 123 accumulation in BBMECs after treatment with 5 µM 
rhodamine 123 in the presence of 10 µM paclitaxel. 
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1.3.4 In situ rat brain perfusion 
 
Unfortunately, cell culture models do not fully incorporate the complexity of the in vivo 
situation, and therefore additional methods must sometimes be used for validation of the 
in vitro findings.  A commonly used technique is the in situ rat brain perfusion in which a 
solution containing test compound is delivered directly into the brain via the carotid 
artery (Smith, 1996).  This technique allows investigators to control both the 
concentration and time of drug administeration.  Furthermore, since the compound is not 
exposed to peripheral metabolizing enzymes, the complexity of the system is minimized.  
Brain uptake kinetics can be examined and permeability constants can be calculated. 
 
1.4 Specific objectives 
 
Researchers are investigating a variety of approaches to improve the brain penetration of 
molecules that have a site of action within the CNS.  The research within our laboratory 
has focused on several approaches for improving the blood brain barrier permeability of 
molecules that are chemotherapeutic as well as neuroprotective.  These molecules could 
hold promise for the treatment of primary brain tumors as well as neurological disorders. 
The specific objective of this project was to explore various chemical approaches to 
improving blood brain barrier permeability using pharmacologically relevant molecules. 
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Specific Aim 1:  Characterize the permeability of structurally modified paclitaxel 
derivatives as well as their recognition by P-glycoprotein in vitro. 
 
Derivatives of paclitaxel in which one or more functional groups have been altered were 
synthesized by the Medicinal Chemistry Department at The University of Kansas.  These 
analogues were designed with the goal of reducing their recognition by the efflux 
transporter P-gp while maintaining their chemotherapeutic effect.  To determine if the 
modifications resulted in changes in recognition by P-gp, an indirect measure of P-gp 
interaction was performed using the rhodamine 123 uptake assay described earlier.  
Compounds showing reduced interaction with P-gp were then monitored for increased 
permeability across BBMECs monolayers to determine if the modification translated into 
improved permeability.    
 
Specific Aim 2:  Characterize the blood brain barrier permeability of the novel 
neuroprotective agent TH-237A. 
 
 GS-164, a microtubule stabilizing compound, which is purported to have a 
mechanism of action similar to that of paclitaxel (Shintani et al., 1997) was found to be 
not only chemotherapeutic but also neuroprotective against the β-amyloid induced 
neurodegeneration that is seen with Alzheimer’s disease.  A variety of GS-164 
stereoisomers were then synthesized and the stereomerically pure cis-isomer TH-237A 
was characterized to determine its ability to cross the blood brain barrier.  Experiments 
include in vitro, in situ and in vivo methods. 
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Specific Aim 3:  Characterize the blood brain barrier permeability of the 
tranylcypromine derivative TCP-FA4. 
 
 Derivates of the monoamine oxidase inhibitor (MAO inhibitor) tranylcypromine 
were synthesized in an attempt to increase blood brain barrier permeability.  The 
derivatives contained lipoamino acids or fatty acids which can ideally enhance the 
lipophilicity of the parent compound and result in improved permeability. The derivative 
TCP-FA4, containing a four carbon fatty acid chain, showed good permeability and its 
mode of transport was investigated.  Additionally, the ability of this compound to be 
neuroprotective was explored and may be linked to its ability to regulate the expression 
of brain derived neurotrophic factor. 
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Chapter 2:  Improving the Blood-Brain Barrier Permeation of Paclitaxel 
 
2.1 Introduction 
 
Although the incidence of primary brain tumor is relatively low, the prognosis is often 
poor.  There are several challenges in treating cancers of the CNS.  First, as with any 
cancer there is the issue of drug resistance.  This phenomenon is due to the 
overexpression of efflux transporters that essentially act as pumps to remove xenobiotics 
from the cancer cells (Dano, 1973; Juliano and Ling, 1976).  Delivery of anticancer 
agents is further complicated within the brain because the blood brain barrier expresses 
these same efflux transporters creating a dual barrier to drug delivery.  Paclitaxel, one of 
the leading anticancer drugs on the market is subject to removal by efflux transporters 
(Fellner et al., 2002) .  Specifically, it is a known substrate for P-glycoprotein (P-gp), one 
of the most well known and well studied of the efflux proteins.  P-gp is a member of the 
ATP-binding cassette (ABC) family.  It has a molecular weight of 170 kDa and consists 
of six transmembrane domains (Juliano and Ling, 1976).  Studies using knockout mice 
show that concentrations of paclitaxel in the brain after IV administration are 12-fold 
higher in P-gp knockout mice compared to wild type (van Asperen et al., 1997). This 
suggests that P-gp is very much responsible for limiting paclitaxel’s entry into the brain.  
One approach to overcome paclitaxel’s poor blood brain barrier permeability is to 
synthesize paclitaxel analogues that retain their pharmacological effect but are no longer 
substrates for P-gp.  Designing a rationale for the synthesis of compounds that will 
circumvent P-gp is quite challenging as the substrate specificity of the protein is still 
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quite poorly understood.  Nevertheless, structure activity relationship (SAR) studies have 
offered some insight into possible recognition elements. 
 
One of the most specific and detailed SAR studies on P-gp was performed by Seelig.  Her 
results suggest that the specific, spatial arrangement of electron-donating groups are a 
feature recognized by P-gp (Seelig, 1998).  Briefly, Type I units consist of electron- 
donating groups separated by 2.5 ± 0.3 Å and Type II units consist of electron-donating 
groups separated by 4.6 ± 0.6 Å with a possible third electron-donating group existing 
between the outer two.  When paclitaxel is examined for these recognition elements, one 
finds it possesses several of these motifs (Figure 2.1).  This is not surprising as Seelig 
postulates that most P-gp substrates contain at least four of these recognition elements 
and essentially all P-gp substrates contain a Type II unit, which proves true for paclitaxel 
as well. 
 
 
Figure 2.1 P-gp recognition elements on paclitaxel (Spletstoser et al., 2006) 
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In addition to considering which substituents are being recognized by P-gp, one must also 
consider which substituents are essential for the chemotherapeutic effect, as these must 
be preserved.  Paclitaxel, works by binding to microtubules within the cell (Jordan et al., 
1993).  Therefore, the features that ensure this binding cannot be altered in the search for 
new analogues possessing reduced interaction with P-gp.  According to prior SAR 
studies, the C7 and C10 positions on paclitaxel are not essential for binding to 
microtubules (Georg et al., 1995).  Therefore, these two positions, which are also Type II 
recognition elements, are a logical choice for modification.  Over 70 analogues of 
paclitaxel were synthesized and a variety of modifications were made, but for simplicity, 
the following chapter will detail three strategies employed for reducing interaction with 
P-gp.  These strategies include: 1) spatial rearrangement at the C10 position via 
epimerization, 2) addition of nutrient-like groups at the C7 and C10 position and 3) 
modification of the C13 side chain to enhance potency combined with strategies one and 
two. 
 
The rhodamine 123 uptake assay using bovine brain microvessel endothelial cells 
(BBMECs) was used as an in vitro model to determine the novel paclitaxel analogues’ 
interaction with P-gp.  Furthermore, permeability studies using BBMECs mounted in 
Side-bi-Side™ chambers were used to predict an analogue’s potential for crossing the 
blood brain barrier if it demonstrated reduced interaction with P-gp. 
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2.2 Experimental 
 
2.2.1 Isolation and maintenance of BBMECs 
 
Bovine brain microvessel endothelial cells (BBMECs) were isolated from the gray matter 
of bovine cerebral cortices by enzymatic digestion followed by centrifugation and then 
seeded as primary cultures following methods described by Audus et al. (Audus and 
Borchardt, 1987). 
 
BBMECs were grown at 37 degrees C in an atmosphere of 5% CO2 and 95% relative 
humidity.  The cells were grown in 50% Minimal Essential Medium and 50% Ham’s F12 
supplemented with 100 µg/mL streptomycin, 100 µg/mL penicillin G, 13 mM sodium 
bicarbonate, 10% platelet poor horse serum,  0.5% endothelial cell growth supplement 
(ECGS), and adjusted to pH 7.4 with 10 mM HEPES.  Cells were seeded on 
polycarbonate 24-well cell culture plates pre-coated with rat tail collagen and fibronectin 
or 0.4µm polycarbonate membranes with the same treatment.  The cells were seeded at a 
density of approximately 25,000-50,000 cells/cm2. 
 
2.2.2 Rhodamine 123 uptake assay 
 
BBMECs were seeded onto 24-well cell culture plates at a density of approximately 
50,000 cells/cm2.  The culture medium was changed every other day starting 72 hours 
after seeding until a confluent monolayer was observed as determined by light 
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microscopy.  Experiments were performed in phosphate-buffered saline supplemented 
with CaCl2, MgSO4, glucose and ascorbic acid (PBSA), pH 7.4. The growth medium was 
first aspirated off and then the cells were rinsed three times with pre-warmed (37 degrees 
C) PBSA.  The monolayers were then equilibrated in 0.5 mL of PBSA for 10 minutes at 
37 degrees C.  Paclitaxel analogues (final concentration: 10 µM) were then added to the 
wells and allowed to equilibrate for 30 minutes.  No analogues were added to the control 
wells.  Rhodamine 123 (final concentration: 5 µM) was then added to all wells and 
allowed to incubate for 2 hours.  Cyclosporin A (CsA, 5 µM), and paclitaxel (10 µM) 
known P-glycoprotein inhibitors, were used as positive controls.  At the end of the 
experiment, the substrate solution was removed by aspiration, and the monolayers were 
immediately rinsed three times with ice-cold PBS.  Each monolayer was solubilized for at 
least 30 minutes (37 degrees C) with 0.5 mL of lysing solution (0.5% v/v Triton X-100 in 
0.2 N NaOH).  Cell lysates were assayed using a microplate fluorescence reader (Bio-Tek 
Instruments, Winooski, VT) at excitation/emission wavelengths of 485 nm/530 nm and 
then quantified against standard curves of rhodamine 123 in lysing solution.  The 
fluorescence of the cell lysates was corrected for autofluorescence of untreated cells.  The 
protein content of each monolayer was then determined using a Pierce BCA protein assay 
reagent kit (Pierce, Rockford, IL).  Results were expressed as nmol of rhodamine 123 
accumulated per mg of cellular protein. 
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2.2.3 Paclitaxel analogue permeability 
 
BBMECs were grown on 0.4 µm polycarbonate membranes in a petri dish coated with rat 
tail collagen and fibronectin.  Once cells had formed a confluent monolayer as 
determined by light microscopy, the membranes were transferred to Side-bi-Side™ 
diffusion chambers as previously described by Audus et al. (Audus and Borchardt, 1987). 
Briefly, each chamber was filled with 3 mL of PBSA and the donor chamber included 10 
µM of test compound.  A temperature of 37 degrees C was maintained with an external 
circulating water bath and chamber contents were stirred with Teflon coated magnetic stir 
bars driven by an external console.   At the various time points (5, 15, 30, 45 and 90 
minutes), 200 µL aliquots were removed from the receiver side and replaced with 200 µL 
of blank PBSA warmed to 37 degrees C.  Samples of the donor solution were also taken 
for analysis.  All samples were analyzed for concentration by LC/MS/MS.  The integrity 
of the cell monolayer was tested post experiment by monitoring the permeability of 
[14-C]-sucrose, a low permeability paracellular marker which should not readily cross the 
cell monolayer.  Radioactive samples were analyzed by liquid scintillation counting. 
 
2.2.4 Sample preparation for LC/MS/MS analysis 
 
Aliquots taken during the permeability studies were aqueous and contained high salt 
concentrations so it was necessary to clean up the samples prior to analysis by 
LC/MS/MS.  Aliquots of 190 µL were taken at the various time points and extracted 
using tert-butylmethylether (t-BME) liquid-liquid extraction.  To each aliquot, 10 µL of 
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docetaxel was added to serve as an internal standard.  To start the extraction, 1.0 mL of t-
BME was added to all samples.  Samples were then vortexed for approximately 10 
minutes followed by a 5 minute centrifugation at 4500 rpm and 4 degrees C.  Samples 
were then placed in a – 80 degrees C freezer and allowed to freeze for at least 15 minutes.  
After freezing of the aqueous portion of the sample, 800 µL of the organic phase was 
transferred to new microcentrifuge tubes and dried in a concentrator under vacuum.  If 
the samples were not immediately analyzed, they were stored at – 80 degrees C until 
analysis.  Before analysis, samples were reconstituted in 200 µL of acetonitrile (60%, 
v/v) containing 0.1% (v/v) formic acid and vortexed.  
 
As part of the method development, the percent solute recovery when using this liquid-
liquid extraction method was determined for paclitaxel as well as docetaxel, the internal 
standard.  Aqueous buffer (PBSA) was spiked with various concentrations of paclitaxel 
and docetaxel at a concentration of 0.5 µg/mL/sample.  Percent recovery values were 
then calculated by comparing the solute peak areas from extracted samples to the peak 
areas from samples spiked directly into mobile phase (60% acetonitrile (v/v) containing 
0.1% formic acid (v/v)).  The average percent recovery for paclitaxel was 59% and 67% 
for docetaxel (Figure 2.2.4.1).  Percent solute recovery was not calculated for every 
single paclitaxel analogue and the assumption was made that the percent recovery for the 
analogues would be similar to that of paclitaxel and docetaxel.  Standards generated from 
extracted buffer samples showed good linearity over a calibration range of 5-5000 ng/mL 
and this was consistent for the various paclitaxel analogues as well.  Figure 2.2.4.2 is a 
calibration curve for paclitaxel and Figure 2.2.4.3 is a representative calibration curve of 
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one of the paclitaxel analogues (TX-297), showing linearity was achieved for the 
analogues as well. 
 
 
 
 
 
      
 % solute recovery 
conc (ng/mL) Paclitaxel in buffer Docetaxel (0.5µg/mL/sample) in buffer 
5 62% 69% 
10 59% 70% 
50 61% 65% 
100 67% 67% 
500 58% 60% 
1000 43% 65% 
2500 61% 66% 
5000 58% 74% 
 
Figure 2.2.4.1 Percent solute recovery for paclitaxel and docetaxel after sample 
preparation by liquid-liquid extraction with t-BME. (n=3, all %RSD < 10%) 
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Figure 2.2.4.2 Typical calibration curve for paclitaxel extracted from aqueous buffer 
(PBSA) using liquid-liquid extraction.  Linearity seen from 5 – 5000 ng/mL. (R2 = 0.998) 
Compound 1 name: Paclitaxel     Method File: Paclitaxel analysis 092506
Correlation coefficient: r = 0.998845, r 2^ = 0.997692
Calibration curve: 8.24355 * x + -345.424
Response type: External Std, Area
Curve type: Linear, Origin: Exclude, Weighting: Null, Axis trans: None
0.0 500.0 1000.0 1500.0 2000.0
ng/mL-345
2.10e4
Response
[Analyte Area * 
(IS conc./IS 
area)] 
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Figure 2.2.4.3 Representative calibration curve of a paclitaxel derivative (TX-297) 
extracted from aqueous buffer (PBSA) using liquid-liquid extraction.  Linearity seen 
from 5 – 5000 ng/mL. (R2 = 0.988) 
Compound 2 name: TX-297     Method File: TX-297 analysis 100306
Correlation coefficient: r = 0.993837, r 2^ = 0.987712
Calibration curve: 30.3283 * x + -2270.43
Response type: External Std, Area
Curve type: Linear, Origin: Exclude, Weighting: Null, Axis trans: None
0.0 500.0 1000.0 1500.0 2000.0
ng/mL-2.27e3
7.77e4
Response
[Analyte Area * 
(IS conc./IS 
area)] 
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2.2.5 Sample analysis by LC/MS/MS 
 
Samples of 20 µL were chromatographed by a Waters 2690 HPLC system using a Zorbax 
Eclipse XDB-C8 column (2.1 x 50 mm, 5 micron) and then directed into the mass 
spectrometer (Micromass™ triple quadrupole) and detected by tandem mass 
spectrometry in positive ion mode using electrospray ionization.  
 
A solvent gradient program was selected for the HPLC analyses as there was minimal 
peak tailing as compared to an isocratic method.  Furthermore, the increased retention 
obtained with a gradient method allowed a diversion of the HPLC eluent between 0 and 5 
minutes which reduced the exposure of the mass spectrometer to possible cellular 
contaminants not eliminated by the sample cleanup procedure.  For the gradient 
parameters, Solvent A was 0.1 % formic acid in nanopure water and Solvent B was 0.1% 
formic acid in acetonitrile.  The gradient used for separation was a linear ramp from 95% 
A to 5% A over 8 minutes, and an equilibration back to 95% A from 8.10 minutes to 
12.10 minutes.  A switching valve was employed to direct the first 5 minutes of eluent to 
waste.  Based on the physicochemical properties of the added substituents within the 
paclitaxel analogues, the retention times shifted appropriately (Figure 2.2.5.1). 
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Figure 2.2.5.1 Representative MS chromatograms of paclitaxel and two derivatives, JO1-
4 and HB4-71, demonstrating the slight shifts in retention time based on the structural 
modifications made.  All chromatograms represent total ion current (TIC). 
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To select the optimal product-ions for analysis, solutions of paclitaxel and the paclitaxel 
analogues, made in 60% (v/v) acetonitrile with 0.1% (v/v) formic acid (25-50 µg/mL), 
were first infused into the mass spectrometer and fragmentation patterns were monitored 
and parameters were optimized.  Paclitaxel and its derivatives were chromatographed and 
detected using multiple reaction monitoring.  Fragmentation within the paclitaxel 
molecule occurred at the C13 side chain and the m/z 854  m/z 569 transition was 
monitored (Figure 2.2.5.2).  For the internal standard docetaxel, the m/z 808  m/z 527 
transition was monitored (Figure 2.2.5.3).  Based on the modifications made within the 
paclitaxel molecule, the set masses and the daughter ion masses were shifted 
appropriately. 
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Figure 2.2.5.2 Electrospray ionization (ESI)-MS/MS (positive ion mode) product-ion 
spectra of paclitaxel (m/z 854) 
 
 
Figure 2.2.5.3 Electrospray ionization (ESI)-MS/MS (positive ion mode) product-ion 
spectra of docetaxel (m/z 808) 
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2.3 Results 
 
2.3.1 Modifications at the C10 position: Effects of spatial rearrangement and oxidative 
state 
 
Since the goal of this project was to structurally modify paclitaxel such that it retained its 
chemotherapeutic effect, but was no longer a substrate for P-gp, the site of modification 
was critical.  Previous studies had shown that the C10 position was not necessary for 
binding to microtubules (Georg et al., 1995), which is how paclitaxel imparts its 
chemotherapeutic effect.  Furthermore, the C10 position can be described as a “Type II 
recognition element” per the classification system created by Seelig (Seelig, 1998).  Since 
Type II recognition elements appear in essentially all P-gp substrates, removal or 
alteration of this moiety was desired and this position was an ideal starting point for 
structural modification.   
 
The paclitaxel molecule has an acetate ester in the β-configuration at the C10 position, 
indicating that the group sits above the baccatin ring structure.  Modifications were made 
such that the acetate ester in the C10 position was changed to the α-configuration to 
determine the effects spatial arrangement has on P-gp recognition.  Furthermore, we 
sought to investigate the effect of changes to the C10 oxidation state on the recognition 
by P-gp.  Thus via ester hydrolysis the acetate ester was converted to a hydroxyl group, 
and we looked at the effects of a hydroxyl group in both the α- and β-configurations.  
This hypothesis that changes in the C10 oxidation state can alter recognition by P-gp is 
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supported by studies that show TXD-258, a novel taxoid, which has a C10- OME group 
in place of the acetate ester, can penetrate the blood brain barrier (Beckers and Mahboobi, 
2003).  Lastly, we looked at the effect a single carbon addition at C10 would have on P-
gp recognition, so the acetate ester group was replaced with a propionate group in the α-
configuration (Figure 2.3.1.1).   
 
Results from the rhodamine 123 uptake assay performed in BBMECs confirm that 
paclitaxel, containing an acetate ester in the β-configuration at the C10 position, is a 
substrate for P-gp. This is indicated by the large increase in intracellular concentration of 
rhodamine 123 when incubated in the presence of paclitaxel as compared to the control.  
The paclitaxel derivative BJT2-57 however has an acetate ester in the α-configuration at 
the C10 position and the rhodamine 123 uptake results indicate a decrease in recognition 
by P-gp as compared to paclitaxel.  This is indicated by the reduction in intracellular 
concentration of rhodamine 123 when incubated in the presence of this derivative (BJT2-
57).  (Figure 2.3.1.2).  These data suggest that recognition by P-gp can be sensitive to 
changes as subtle as absolute configuration. 
 
The paclitaxel derivatives BJT2-55 and JO1-4 have a hydroxyl group in the α- and β-
configuration, respectively, at the C10 position.  This change in C10 oxidation state 
compared to paclitaxel appears to decrease recognition by P-gp as indicated by a reduced 
intracellular concentration of rhodamine 123. (Figure 2.3.1.2).  This reduction in 
recognition can be explained by the fact that the C10 position is no longer a Type II 
recognition element, but has been converted to a weaker Type I motif via hydrolysis. 
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The addition of a single carbon atom, yielding a propionate group at the C10 position 
(JTS6275) when in the α-configuration does not appear to result in any decreased 
recognition by P-gp relative to paclitaxel. (Figure 2.3.1.2) 
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Figure 2.3.1.1 Structural modifications of paclitaxel showing changes in absolute 
configuration and oxidation state at the C10 position 
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Figure 2.3.1.2 Rhodamine 123 uptake assay results indicate that derivatives BJT 2-55, 
JO1-4 and BJT2-57 exhibit reduced interaction with P-gp relative to paclitaxel.  
Cyclosporin A (CsA), a known substrate for P-gp, was used as a positive control. (** 
Denotes p<0.01 compared to paclitaxel as determined by ANOVA, Data ± SD, n=3).  
Structures found on page 48. 
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The same structural modifications were made on docetaxel to see if the trend held within 
a structurally similar series.  (Structures found in Appendix 2, page 168).  Docetaxel 
(Taxotere®) is a semi-synthetic analogue of paclitaxel and it differs in two positions.  In 
the 3' position within the C13 sidechain, paclitaxel has a benzoyl group.  This group has 
been converted to a t-butoxy carbonyl group within the docetaxel molecule.  Also, in 
place of paclitaxel’s β-acetate ester at the C10 position, there is an α-hydroxy group 
within docetaxel (Figure 2.3.1.3) 
 
 
 
Figure 2.3.1.3 Structure of docetaxel, a semi-synthetic analogue of paclitaxel 
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regardless of configuration (BJT1-97 and docetaxel) (Figure 2.3.1.4).  No effect is seen 
with an α-configuration propionate group at C10 (SLA269).  These data further confirm 
that recognition by P-gp can be affected by changes as subtle as absolute configuration 
and C10 oxidation state.  Although the same trend was seen within this series, relative to 
paclitaxel, none of these derivatives exhibited a statistically significant reduction in 
interaction with P-gp.  Therefore, they are not expected to have improved permeability 
compared to paclitaxel.   
    
 
 
 
 
 
 
 
 
 
Figure 2.3.1.4 Rhodamine 123 uptake assay results indicate that conversion of the C10 
acetate ester to the α-configuration (BJT 1-109) reduces P-gp interaction compared to 
BJT 2-59 containing an acetate ester in the β-configuration.  Interaction can also be 
reduced when there is a hydroxyl group at the C10 position regardless of configuration 
(BJT 1-97 and docetaxel). (** Denotes p<0.01 compared to paclitaxel as determined by 
ANOVA, Data ± SD, n=3).  Structures found in Appendix 2, page 168. 
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The same structural modifications were tested again using Taxol C as a backbone.  
(Structures found in Appendix 2, page 169).  Paclitaxel is extracted from the Pacific yew 
tree (Taxus brevifolia), and during this extraction process there are a variety of other 
taxanes present at trace levels, one of which is Taxol C.  The only structural difference 
from paclitaxel occurs at the 3' position.  The benzoyl group of paclitaxel is replaced with 
a 5 carbon chain on Taxol C (Figure 2.3.1.5) 
 
 
 
 
 
 
 
 
 
Figure 2.3.1.5 Structure of Taxol C, a trace taxane present during the extraction of 
paclitaxel. 
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(JTS6209 and JTS6263).  Lastly, no change in recognition is seen with a propionate 
group at the C10 position (JTS6221) (Figure 2.3.1.6). 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.1.6 Rhodamine 123 uptake assay results indicate that conversion of the C10 
acetate ester to the α-configuration (JTS1279) reduces P-gp interaction compared to 
Taxol C containing an acetate ester in the β-configuration.  Interaction can also be 
reduced when there is a hydroxyl group at the C10 position regardless of configuration 
(JTS6209 and JTS6263).  (** Denotes p<0.01 compared to paclitaxel as determined by 
ANOVA, Data ± SD, n=3).  Structures found in Appendix 2, page 169. 
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substrates for P-gp, at greater concentrations their interaction with P-gp was revealed 
(Figure 2.3.1.7) 
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Figure 2.3.1.7 Rhodamine 123 uptake in the presence of increasing concentrations of 
JTS6209 and JTS6263. (** Denotes p<0.01 compared to negative control (rhodamine 
alone) as determined by ANOVA, Data ± SD, n=3).  Structures found in Appendix 2 
page 169. 
** 
** 
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** 
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2.3.2 Effect of nutrient-like groups at the C7 or C10 position 
 
The second strategy utilized was one in which we attached nutrient-like groups at the C7 
and C10 positions.  Again, we focused on these positions because they are not essential 
for binding to microtubules and modifications at these sites should not result in dramatic 
changes in potency.  The rationale behind attaching nutrient-like groups is that there are 
systems in place at the blood brain barrier responsible for the active uptake of nutrients.  
Such systems include the large neutral amino acid transporter (LAT1), monocarboxylate  
transporter (MCT1), glucose transporter (GLUT1)and various peptide transporters among 
others (Pardridge, 2003). 
 
By attaching a nutrient-like group to the paclitaxel molecule there is the possibility of 
recognition by one of these uptake transporters and as a result increased permeability 
across the blood-brain barrier.  First, the type of nutrient-like group to attach must be 
decided upon, and then the effects on P-gp recognition must be studied.  Ideally, 
attachment of a nutrient-like group could decrease recognition by P-gp and at the same 
time target recognition by a nutrient uptake transporter expressed within the brain 
endothelial cells. 
 
The first series of compounds had succinate derivatives attached at either the C7 or C10 
position.  Previous studies in our laboratory had shown that a succinate group attached at 
the C10 position of paclitaxel resulted in a molecule with greatly improved permeability 
across the blood-brain barrier (Rice et al., 2005).  We sought to investigate whether the 
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acid moiety was essential to this reduction in P-gp interaction.  The nutrient-like groups 
attached consisted of amide esters of succinate and methyl esters of succinate (Figure 
2.3.2.1). 
 
 
 
Figure 2.3.2.1 Paclitaxel derivatives containing succinate derivatives at either the C7 or 
C10 position.  (C7 modifications: TX-297, TX-195, TX-293 and TX2-25, C10 
modifications: BJT1-205, JO3-57, JO1-57 and BJT2-45) 
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Paclitaxel derivatives containing succinate-like groups were tested for interaction with P-
gp using the rhodamine 123 uptake assay and results showed that nutrient group 
placement at the C7 position did not reduce interaction with P-gp and in some cases 
actually increased this interaction.  However, when the same succinate-like modifications 
were made at the C10 position, the desired decrease in interaction with P-gp was 
observed.  One exception was BJT 2-45, the methyl ester derivative, which exhibited 
interaction with P-gp similar to paclitaxel. These data again emphasized the importance 
of the C10 position for recognition of paclitaxel by P-gp.  All compounds were tested at a 
range of concentrations (1, 2.5, 5, 10, 25 and 50 µM) while maintaining the same 
concentration of rhodamine 123 (5 µM) (Figures 2.3.2.2 and 2.3.2.3) 
 
These studies suggest that placement of nutrient-like groups may be more effective at the 
C10 position, versus the C7 position, as they reduce interaction with P-gp.  Furthermore, 
these data reiterate the importance of the C10 position in P-gp’s recognition of the 
paclitaxel molecule.   
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Figure 2.3.2.2 Paclitaxel derivatives containing succinate ester groups at the C7 position 
generally have interaction with P-gp equivalent to paclitaxel and in some cases have 
increased interaction. (Data ± SD, n=3).  Structures found on page 56. 
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Figure 2.3.2.3 Paclitaxel derivatives containing succinate ester groups at the C10 
position generally have reduced interaction with P-gp compared to paclitaxel, with the 
exception of BJT 2-45, the methyl ester derivative. (Data ± SD, n=3). Structures found on 
page 56. 
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The second series of compounds had biotin attached at either the C7 or C10 position.  
(Structures found in Apendix 2, pages 170-171).  Spector et al. (Spector and Mock, 1987) 
have shown that a biotin transport system exists at the blood brain barrier.  Furthermore, 
previous studies in our laboratory have confirmed the existence of a biotin transport 
system in BBMECs assuring us that ours is a good model to use for the testing of these 
compounds (Shi et al., 1993).  Biotin was attached at either the C7 or C10 position and 
the effect of this modification on recognition by P-gp was first examined.  Both 
compounds, JTS4169 (biotin attachment at C7) and JO2-38C (biotin attachment at C10) 
demonstrated a decreased interaction with P-gp in the rhodamine 123 uptake assay 
(Figure 2.3.2.4).  Again, this strategy resulted in some paclitaxel analogues that show 
reduced interaction with P-gp that may also have improved permeability across the blood 
brain barrier. 
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Figure 2.3.2.4 Paclitaxel derivatives containing a biotin group at the C7 or C10 position 
have reduced interaction with P-gp compared to paclitaxel. (** Denotes p<0.01 compared 
to paclitaxel as determined by ANOVA, Data ± SD, n=3).  Structures found in Appendix 
2, pages 170-171. 
** 
** ** 
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2.3.3 Modifications at the C13 position to enhance potency 
 
The third chemical modification strategy included modifications at the C7 and C10 
positions, as well as the C13 side chain.  Ojima et al. have reported that docetaxel 
derivatives (t-butoxy carbonyl in place of the benzoyl in the 3' position) containing an 
isobutyl or isobutenyl group in place of the 3' phenyl group exhibited increased 
cytotoxicity against the drug-resistant human breast cancer cell line expressing the MDR 
phenotype (NCI/ADR-RES) (Ojima et al., 1996).  Therefore, the goal of this strategy was 
to enhance the potency through modifications of the C13 side chain while still using the 
modifications at the C7 and C10 positions that had been shown previously in our lab to 
reduce interaction with P-gp.  A large library of analogues containing this C13 
modification was generated.  Unfortunately, modification at the C13 residue appears to 
consistently result in a molecule displaying strong interaction with P-gp (Figure 2.3.3.1).  
The exceptions were three analogues, all of which had a nutrient-like group at the C10 
position (Figure 2.3.3.2).  (Structures found on page 70).  HB4-63 and HB4-91 both 
contained a succinic acid group at the C10 position and HB4-91 contained an amide ester 
of succinate at the C10 position.  The most surprising result was that HB4-99, which also 
contained a succinate ester at the C10 position, but had an isobutyl group at the 3' 
position, did not show a reduction in P-gp interaction.  This result was not expected and 
to date cannot be explained. 
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Derivative 3' position C7  C10 Interacts w/ P-gp 
HB4-37 isobutenyl β-hydroxy β-hydroxy yes 
HB2-199 isobutenyl β-hydroxy α-hydroxy yes 
Taxol 273 isobutenyl β-hydroxy β-acetyl yes 
HB2-243 isobutenyl β-hydroxy α-acetyl yes 
HB4-79 isobutyl β-hydroxy β-hydroxy yes 
HB2-251 isobutyl β-hydroxy α-hydroxy yes 
Taxol 277 isobutyl β-hydroxy β-acetyl yes 
HB4-83 isobutyl β-hydroxy α-acetyl yes 
       
HB4-63 isobutenyl β-hydroxy β-succinic acid no 
HB4-71 isobutenyl β-hydroxy β-amide ester of succinate no 
HB4-153 isobutenyl β-succinic acid β-acetyl yes 
HB4-155 isobutenyl β-amide ester of succinate β-acetyl yes 
HB4-91 isobutyl β-hydroxy β-succinic acid no 
HB4-99 isobutyl β-hydroxy β-amide ester of succinate yes 
HB4-195 isobutyl β-succinic acid β-acetyl yes 
HB4-173 isobutyl β-amide ester of succinate β-acetyl yes 
       
HB4-203 isobutenyl β-amide ester of succinate β-propionate yes 
HB4-201 isobutenyl β-succinic acid β-propionate yes 
HB4-209 isobutyl β-amide ester of succinate β-propionate yes 
HB4-207 isobutyl β-succinic acid β-propionate yes 
          
 
Figure 2.3.3.1 Library of analogues containing C13 modifications to enhance potency as 
well as C7 and C10 modifications attempting to reduce interaction with P-gp.  Structures 
of compounds showing reduced interaction with P-gp found on page 70. 
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Figure 2.3.3.2 Rhodamine 123 uptake assay results for analogues containing C13 
modifications to enhance potency as well as C7 and C10 modifications attempting to 
reduce interaction with P-gp.  Only three analogues (HB4-63, HB4-71 and HB4-91) 
showed a decrease in interaction with P-gp. (** Denotes p<0.01 compared to paclitaxel 
as determined by ANOVA, Data ± SD, n=3).  Structures found on page 70. 
 
2.3.4 BBMEC permeability of derivatives showing reduced interaction with P-gp 
 
For those analogues showing a reduction in interaction with P-gp, we wanted to 
investigate whether or not this translated into improved permeability.  BBMECs mounted 
in Side-bi-Side™ chambers were used to test the permeability of the various analogues.  
The apparent permeability values of the derivatives were calculated using the following 
equation:  
 
** ** ** ** 
 63 
Papp =  (∆Q/∆t)/ A x C0 
 
where ∆Q/∆t is the linear appearance of the test compound in the receiver chamber, A is 
the cross sectional area of the cell monolayer (0.636 cm2) and C0 is the initial 
concentration of the test compound in the donor chamber at t = 0. 
 
From the first strategy, three analogues showed a reduction in interaction with P-gp 
relative to paclitaxel.  These analogues included BJT2-57, which possesses an α- acetate 
ester at the C10 position, as well as BJT2-55 and JO1-4 which both possess a C10 
hydroxyl group in the α- and β-configurations respectively.  Permeability studies 
performed with these analogues in BBMECs unfortunately showed no increase in 
permeability relative to paclitaxel and in fact had lower permeability (Figure 2.3.4.1) 
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Figure 2.3.4.1 Permeability of analogues BJT2-55, JO1-4, and BJT2-57 across BBMEC 
monolayers.  No improvement in permeability was seen relative to paclitaxel. (Data ± 
SD, n=4).  Structures found on page 48. 
 
From the second strategy, succinate-like groups attached to the C10 position generally 
reduced interaction with P-gp.  Three analogues were expected to show improved 
permeability and included BJT1-205, an amide ester of succinate as well as JO1-57 and 
JO3-57 which were amide esters of succinate with increasing methylation.  
Unfortunately, once again, an improvement in permeability compared to paclitaxel was 
not seen.  While BJT1-205 had equivalent permeability compared to paclitaxel, JO1-57 
and JO3-57 had decreased permeability (Figure 2.3.4.2) 
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Figure 2.3.4.2 Permeability of analogues JO1-57, JO3-57 and BJT1-205 across BBMEC 
monolayers.  No improvement in permeability was seen relative to paclitaxel. (Data ± 
SD, n=4).  Structures found on page 56. 
 
The other strategy in which nutrient-like groups were attached, included the two 
analogues which had biotin attached at either the C7 or C10 position.  In both cases, a 
reduction in interaction with P-gp was observed; however, neither analogue showed an 
increase in permeability when tested using BBMECs (Figure 2.3.4.3). 
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Figure 2.3.4.2 Permeability of analogues JO2-38C and JTS4169 across BBMEC 
monolayers.  No improvement in permeability was seen relative to paclitaxel. (Data ± 
SD, n=4).  Structures found in Appendix 2, pages 170-171. 
 
The third and last strategy yielded three analogues that showed reduced interaction with 
P-gp.  These analogues included HB4-63, which had an isobutenyl group in the 3' 
position and a succinic acid moiety at C10, HB4-91, which also had a succinic acid group 
at the C10 position, but an isobutyl group at the 3' position and HB4-71 which had an 
amide ester of succinate at the C10 position and an isobutenyl group at the 3' position.  
Once again, these analogues did not have improved permeability compared to paclitaxel 
as expected (Figure 2.3.4.3) 
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Figure 2.3.4.3 Permeability of analogues HB4-63, HB4-91 and HB4-71 across BBMEC 
monolayers.  No improvement in permeability was seen relative to paclitaxel. (Data ± 
SD, n=3).  Structures found on page 70. 
 
2.3.5 Mass balance determination of select permeability studies 
 
For permeability studies using paclitaxel analogues that contained nutrient-like groups, a 
mass balance calculation was performed.  The donor chamber was sampled at time zero 
to obtain an initial concentration as well as at the end of the study to determine a final 
concentration.  The cumulative concentration within the receiver chamber over time was 
also accounted for.  Results showed some analogues to have a low mass balance 
compared to paclitaxel which has an average mass balance of approximately 94% (Figure 
2.3.5.1).  No trend could be seen among the compounds showing poor mass balance.  It 
should also be noted that the cells were not examined for intracellular contents; therefore, 
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compound within the cells was not accounted for when calculating the mass balance. For 
structures of derivatives for which a mass balance was determined see Figure 2.3.5.2. 
 
 
Derivative % Mass Balance 
paclitaxel 93.4% 
JO1-57 96.0% 
JO3-57 64.1% 
BJT1-205 59.3% 
JO2-38C 55.6% 
JTS4169 43.9% 
HB4-63 62.7% 
HB4-91 62.3% 
HB4-71 94.9% 
 
Figure 2.3.5.1 Mass balance calculations for permeability studies of derivates containing 
nutrient-like groups.  Structures found in Figure 2.3.5.2. 
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Figure 2.3.5.2 Structures of derivatives for which a mass balance was determined 
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Figure 2.3.5.2 (cont.) Structures of derivatives for which a mass balance was determined 
 
CH3
CH3
CH3
O
O
NH
CH3 CH3
O
O
OH
CH3
OH
BzO
AcO
O
CH3
O
H
OH
O
O
O
OH
CH3
CH3
CH3
O
O
NH
O
O
OH
CH3
OH
BzO
AcO
O
CH3
O
H
OH
O
O
O
OH
CH3 CH3
CH3
CH3
CH3
O
O
NH
CH3 CH3
O
O
OH
CH3
OH
BzO
AcO
O
CH3
O
H
OH
O
O
O
NH2
Derivative name 
HB4-63 
 
 
 
 
 
 
 
 
 
 
 
 
HB4-91 
 
 
 
 
 
 
 
 
 
 
 
HB4-71 
 71 
2.4 Discussion 
 
Paclitaxel, a very successful chemotherapeutic agent, is unable to be used to treat cancers 
located within the CNS because it is a substrate for P-gp, one of the many efflux 
transporters located at the blood brain barrier that is responsible for keeping drugs out of 
the brain.  One approach used to evade P-gp is modification of the structure of existing 
pharmacological agents such that they retain their pharmacological effect, but are no 
longer substrates for P-gp.  This approach was taken by our laboratory in collaboration 
with Dr. Gunda Georg and structural analogues of paclitaxel were synthesized and their 
interactions with P-gp were evaluated.  A variety of modification strategies were 
employed including 1) Spatial rearrangement at the C10 position via epimerization, 2) 
Addition of nutrient-like groups at the C7 and C10 position and 3) Modification of the 
C13 side chain to enhance potency combined with strategies one and two.  For those 
analogues demonstrating reduced interaction with P-gp, the permeability of the analogue 
across monolayers of BBMECs was determined in vitro to predict if it would have 
improved permeability across the blood brain barrier. 
 
Each of the modification strategies produced several compounds that demonstrated a 
reduction in P-gp interaction based on the results from the rhodamine 123 uptake assay.  
Although an increase in permeability was expected based on the rhodamine 123 results, 
an improvement in permeability relative to paclitaxel unfortunately was not seen.  For 
those derivatives in which subtle changes in stereochemistry and the oxidation state of 
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the C10 carbon were made, the low permeability was surprising, as we had hoped to see 
an improvement in permeability once interaction with P-gp was minimized.   
 
For those compounds which had a nutrient-like group attached, the low permeability 
results were not entirely surprising even though they were disappointing.  Once the 
nutrient-like groups were attached (either succinate-like groups or biotin) the size of the 
molecule increased substantially.  For example, the molecules containing biotin at the C7 
and C10 positions had molecular weights of over 1000 Da.  Studies have shown that 
compounds with substantially lower molecular weights (MW: 300-500 Da) have a better 
chance of success of crossing the blood brain barrier in a passive manner (Mahar Doan et 
al., 2002).  Paclitaxel, which already has a very large molecular weight (MW: 853.92), is 
at an even greater disadvantage once these large nutrient-like groups are attached.  If the 
uptake transporters that were being targeted had been able to recognize these paclitaxel 
molecules, then size would not have been an issue, however, it appears that recognition 
was not achieved. 
 
The issue of poor mass balance in some of the permeability assays may be explained by 
the increase in size and lipophilicity of the molecules.  There is the possibility that those 
compounds showing poor mass balance may be getting caught up in the lipid bilayer of 
the cell membrane and not permeating across to the receiver side.  Additionally, since the 
solubility of every derivative was not calculated, there is the possibility of precipitation 
over the course of the permeability study.  Since the intracellular contents of the BBMEC 
monolayer are not being analyzed, this could also account for the loss of mass.  
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Furthermore, there are a multitude of uptake transporters expressed at the blood brain 
barrier, and although many of these transporters may be expressed in the BBMECs, they 
have not been fully characterized.  Additionally, the luminal versus abluminal expression 
patterns are not fully understood.  Therefore, there is the possibility that these paclitaxel 
analogues containing nutrient-like groups are recognized by an uptake transporter at the 
luminal side, but there is no expression of that transporter at the abluminal side to 
facilitate the transport of the molecule out of the other side of the cell. 
 
2.5 Conclusions 
 
Structural analogues of paclitaxel were synthesized in the hopes of creating molecules 
that retained their pharmacological effect, but were no longer substrates for the efflux 
transporter P-gp.  A variety of modification strategies were employed and results showed 
that P-gp recognition could in fact be altered with minor structural changes.  Studies also 
reiterated the complex substrate specificity of P-gp.  Changes as subtle as absolute 
configuration at one chiral center or the oxidation state at the C10 carbon were enough to 
alter recognition by P-gp.  The importance of the C10 position to P-gp’s recognition of 
paclitaxel was also highlighted.  Although a reduction in interaction with P-gp did not 
translate to an improvement in permeability for this set of compounds, the data help 
improve our understanding of paclitaxel’s recognition by P-gp and may direct chemistry 
efforts in the future. 
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Although paclitaxel and the structural analogues described herein would penetrate into 
the CNS at very low levels, recent research suggests there may be some utility of these 
microtubule stabilizing compounds as neuroprotective agents even at these 
concentrations (Michaelis et al., 2005).  Studies have shown that taxanes, as well as other 
structurally diverse microtubule stabilizing compounds, may protect neurons against the 
β-amyloid induced neurodegeneration seen in Alzheimer’s disease.  A collaboration with 
The University of Kansas, Department of Pharmacology and Toxicology allowed us to 
test some of the paclitaxel analogues in a neuronal survival assay (data not shown).  
Additionally, this research prompted us to investigate other microtubule stabilizing 
compounds that possess improved physicochemical characteristics relative to paclitaxel 
and may more easily cross the blood brain barrier, in a passive manner. 
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Chapter 3:  TH-237A: A Novel Neuroprotective Agent Exhibiting Favorable 
Permeation Across the Blood Brain Barrier 
 
3.1 Introduction 
 
Studies have shown that various paclitaxel analogues at nanomolar concentrations have 
the ability to protect neurons against β-amyloid (Aβ) induced neurotoxicity found in 
Alzheimer’s (Michaelis et al., 2005).  It is believed that the mechanism behind this effect 
is in part due to the microtubule stabilizing properties of the taxanes.  Aβ deposition 
results in hyperphosphorylation of τ protein, a microtubule associated protein, which 
leads to neurofibrillary tangles that in turn leads to neuronal loss and cell death 
(Michaelis et al., 1998).  Since taxanes, such as paclitaxel, promote microtubule stability 
(Jordan et al., 1993), they may help preserve the structure of the microtubule network 
from the destabilizing activity of Aβ.  Although our laboratory has worked extensively 
with paclitaxel derivatives, we were prompted to investigate other microtubule stabilizing 
compounds that have inherently better physicochemical properties for blood brain barrier 
transport. 
 
In 1997, Shintani et al. reported that GS-164, a small synthetic compound, stimulated 
microtubule assembly in a mechanism similar to that of paclitaxel (Taxol®) (Shintani et 
al., 1997).  The R/R isomer was determined to be responsible for the microtubule 
stabilizing properties.  A variety of stereoisomers of GS-164 have been synthesized in 
collaboration with Dr. Gunda Georg and the stereomerically pure cis-isomer, denoted 
TH-237A (Figure 3.1), showed excellent neuroprotective effects.  Furthermore, this 
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compound showed excellent promise of permeation across the blood brain barrier based 
on its low molecular weight and improved solubility relative to paclitaxel. 
 
N
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Figure 3.1 Structure of TH-237A.  
 
The studies outlined herein demonstrate TH-237A’s excellent neuroprotective properties 
as well as its potential to cross the blood brain barrier.  A variety of in vitro, in situ and in 
vivo models were employed to predict TH-237A’s brain penetration.   
 
In collaboration with Dr. Mary Lou Michaelis’ laboratory in the Department of 
Pharmacology and Toxicology at The University of Kansas, we investigated the 
neuroprotective properties of TH-237A in a neuronal culture after exposure to Aβ 
peptides.  Primary neurons were isolated from embryonic Sprague-Dawley rats, grown in 
culture (Michaelis et al., 1994) and exposed to either Aβ25-35 or Aβ1-42 in the presence or 
absence of TH-237A at concentrations ranging from 0.5 to 60 nM.  The neurons were 
treated with TH-237A for 2 hours prior to exposure to the Aβ peptides.  Changes in 
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neuronal survival following treatment with TH-237A were evaluated using the Live/Dead 
assay (Michaelis et al., 1998; Michaelis et al., 2005).  The EC50 for TH-237A 
(concentration that leads to a 50% increase in neuronal survival in the presence of the Aβ 
peptides) was 5 nM, demonstrating that it had excellent neuroprotective properties. 
 
A neuroprotective agent’s success as a pharmaceutical agent however depends on its 
ability to reach the site of action within the brain.  There are a variety of barriers to brain 
penetration including anatomical barriers (i.e.: tight junctions, reduced pinocytosis, 
glycocalyx, etc.) (Reese and Karnovsky, 1967; Brightman and Reese, 1969), metabolic 
barriers (i.e.: peptidases, phase I and phase II enzymes, etc) (Spatz and Mrsula, 1982) and 
an electrostatic barrier due to sulfated glycoproteins at the cell surface.  Another major 
barrier to brain penetration is the existence of efflux transporters expressed by the brain 
endothelial cells (Pardridge, 1998).  If a drug is recognized as a substrate for one of these 
efflux transporters, the permeation across the blood brain barrier can be significantly 
compromised.  Of the various efflux transporters, one of the most well known and most 
often studied is P-glycoprotein (P-gp).  The rhodamine 123 uptake assay used in 
conjunction with bovine brain microvessel endothelial cells (BBMECs) is an efficient 
way to screen compounds in vitro for their recognition by P-gp (Fontaine et al., 1996).  
TH-237A was tested at a range of concentrations and showed no alteration in rhodamine 
123 uptake, suggesting it was not a substrate for P-gp.   
 
To test for the recognition of TH-237A by other efflux transporters as well as uptake 
transporters, directional permeability studies were performed in vitro using BBMECs.  In 
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these studies, radiolabeled test compound ([3H]-TH-237A) was added to either the 
luminal or abluminal side of the cells and permeability was monitored over time.  A 
directional dependent difference in permeability is an indication that an active process is 
occurring.  In studies with [3H]-TH-237A, no directional permeability differences 
existed, indicating that the permeation of TH-237A was a passive process. This finding 
was confirmed with the use of temperature dependent permeability studies in vitro with 
BBMECs from which an Arrhenius plot was generated and an activation energy was 
calculated.   
 
Since in vitro permeability studies with BBMECs suggested very favorable permeability 
across the blood brain barrier, TH-237A was tested using the in situ rat brain perfusion 
model.  [3H]-TH-237A infused directly into the carotid artery of anesthetized rats showed 
very good brain penetration after just 60 seconds of perfusion. 
 
In collaboration with the Higuchi Biosciences Center, TH-237A was then tested in vivo in 
balb/C rats and complete pharmacokinetics parameters were determined.  Blood was 
collected via cardiac puncture at multiple time points and brain tissue was harvested.  
After either intravenous injection into the tail vein or subcutaneous injection, significant 
amounts of TH-237A entered the brain, supporting the in vitro and in situ predictions that 
TH-237A would have very good brain penetration   Furthermore, the high brain 
concentrations were achieved rapidly and drug loss from the brain was quite slow with a 
half-life on the order of hours.   
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3.2 Experimental 
 
3.2.1 Synthesis of TH-237A  
Sythesis of TH-237A was performed by the Georg laboratory at The University of 
Kansas.  A suspension of p-fluorobenzaldehyde (27 g, 0.22 mol) and 
tris(hydroxymethyl)aminomethane (13 g, 0.11 mol) in toluene  (350 ml) was heated at 
reflux temp with azeotropic removal of water for 12 hrs. The reaction mixture was 
concentrated, stirred at room temperature and the precipitated unreacted p-
fluorobenzaldehyde was filtered off. The residue obtained after removal of solvent was 
subjected to flash chromatography on silica gel using hexane:ethylacetate (4:1 and 1:1). 
Crystallization of the respective fractions afforded pure compound in a yield of 66% 
based on equimolar product distribution ratio. The structure of the product was assigned 
by spectral data and the relative stereochemistry of TH-237A was assigned from single 
crystal X-ray diffraction data.  For radiolabeled studies, the TH-237A was custom labeled 
with tritium [3H] by Moravek Biochemicals, Inc. (Brea, CA). 
 
3.2.2 Isolation and maintenance of BBMECs 
 
Bovine brain microvessel endothelial cells (BBMECs) were isolated from the gray matter 
of bovine cerebral cortices by enzymatic digestion followed by centrifugation and then 
seeded as primary cultures following methods described by Audus et al. (Audus and 
Borchardt, 1987). Isolated BBMECs were seeded at a density of approximately 50,000 
cells/cm2 onto 24-well culture plates or 100 mm culture dishes (Corning Costar, Acton, 
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MA) containing Nucleopore® polycarbonate membranes (pore size 0.4 µm) (Whatman, 
Florham Park, NJ) pretreated with rat-tail collagen prepared in house and fibronectin 
(Sigma-Aldrich, St. Louis, MO).  Culture medium was prepared and cells were 
maintained as described in the experimental section of Chapter 2. 
 
3.2.3 Rhodamine 123 uptake assay 
 
In this assay, rhodamine 123 is used as a surrogate P-glycoprotein (P-gp) substrate 
(Fontaine et al., 1996).  The effect of the test compound on rhodamine123 is determined 
by monitoring intracellular fluorescence. If the test compound is a substrate for P-gp, 
then addition of the compound will increase rhodamine 123 uptake relative to the 
negative control.  BBMECs were seeded onto 24-well plates coated with rat tail collagen 
and fibronectin at a density of approximately 50,000 cells/cm2.  Culture medium was 
replaced every other day until cells formed a confluent monolayer.  At the start of the 
experiment, BBMECs were rinsed with warm PBSA (PBS containing CaCl2, MgSO4, 
glucose and L-ascorbic acid) and allowed to acclimate to the warm PBSA for 10 minutes.  
The PBSA was removed and solutions of TH-237A (conc.: 1-50µM) were added to the 
wells and allowed to incubate for 30 minutes at 37 degrees C in a hotbox. Rhodamine 
123 was then added to all wells at a concentration of 5 µM and the plate was returned to 
the hotbox.  Cells were incubated for an additional 2 hours.  After the incubation, cells 
were quickly rinsed with ice cold PBS several times.  Lysis buffer (0.5% v/v Triton X-
100 in 0.2 N NaOH) was then added to all wells and allowed to solubilize cells for at 
least 30 minutes.  200 µL aliquots were taken from all wells to determine Rhodamine 123 
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concentration and 10 µL aliquots were taken from all wells to determine protein 
concentration.  Rhodamine 123 concentrations were determined on a Biotek FL600 
Microplate Fluorescence Reader (excitationλ: 485, emissionλ: 530).  Protein 
determination was performed using a Pierce BCA Protein Assay Kit (Pierce, Rockford, 
IL) and samples were read on an EIA reader at 540 nm. 
 
 3.2.4 Permeation of TH-237A across BBMEC monolayers 
 
3.2.4.1 Bi-directional permeation studies 
 
BBMECs were grown on 0.4 µm Nucleopore® polycarbonate membranes in a 100 mm 
culture dish coated with rat tail collagen and fibronectin.  Once cells had formed a 
confluent monolayer as determined by light microscopy, the membranes were transferred 
to Side-bi-Side™ diffusion chambers as previously described by Audus et al. (Audus et 
al., 1996; Audus et al., 1998).  Briefly, each chamber was filled with 3 mL of PBSA and 
either the luminal or abluminal donor chambers contained 10 µM of unlabeled TH-237A 
and a trace amount of [3H]-TH-237A.  A temperature of 37 degrees C was maintained 
within the chamber with an external circulating water bath and chamber contents were 
stirred with Teflon coated magnetic stir bars driven by an external console.   At the 
various time points (5, 15, 30, 45 and 90 minutes), 200 µL aliquots were removed from 
the receiver side and replaced with 200 µL of blank PBSA warmed to 37 degrees C.  
Samples of the donor solution were also taken for analysis.    The integrity of the cell 
monolayer was tested post experiment by monitoring the permeability of [14C]-sucrose, a 
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paracellular marker which should not readily cross the cell monolayer.  All samples were 
analyzed for concentration by liquid scintillation counting. 
 
3.2.4.2 Temperature dependent permeation studies 
 
Again, BBMECs were grown on 0.4 µm Nucleopore® polycarbonate membranes then 
transferred to Side-bi-Side™ diffusion chambers. 10 µM TH-237A with trace amounts of 
[3H]-TH-237A was added to the luminal chambers and 200µL samples were taken from 
the abluminal chamber at various time points (5, 15, 30, 45, and 90 minutes).  Permeation 
of TH-237A was calculated at a range of temperatures (4, 8, 12, 16, 20, 26, 30 and 37 
degrees C) in order to determine an activation energy.  The integrity of the cell 
monolayer was tested post experiment by monitoring the permeability of [14C]-sucrose 
and samples were analyzed by liquid scintillation counting.   
 
3.2.4.3 Inhibition studies using [3H]-TH-237A 
 
BBMECs were grown in 24-well plates coated with rat tail collagen and fibronectin at a 
density of approximately 50,000 cells/cm2.  Upon confluency, cells were washed several 
times with warm PBSA and allowed to acclimate to the PBSA for approximately 10 
minutes.  [3H]-TH-237A (1 nM) and non-radiolabeled TH-237A (0.5 nM, 1 nM, 10 nM, 
10 0nM, 1 µM, 10 µM and 100 µM) were added (N=3) to the cells and allowed to 
incubate for 1 hour at 37 degrees C in a shaking hotbox.  At the end of the incubation, 
cells were rinsed several times with ice cold PBS and lysis buffer (0.5% v/v Triton X-100 
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in 0.2 N NaOH) was then added to all wells and allowed to solubilize cells for at least 30 
minutes.  200 µL aliquots of the lysed cells were then taken for analysis by liquid 
scintillation counting and 10 µL of lysed cells were taken for protein determination using 
a Pierce BCA Protein Assay Kit (Pierce, Rockford, IL).  Inhibition of radiolabeled TH-
237A uptake by increasing amounts of non-radiolabeled TH-237A was investigated. 
 
3.2.5 In situ rat brain perfusion 
 
Adult male Sprague-Dawley rats, weighing approximately 250-350 g were purchased 
from Charles River and the in situ rat brain perfusion described by Smith and Allen 
(Smith and Allen, 2003) was used.  Rats were administered, by subcutaneous injection, a 
complete anesthetic cocktail including 0.37 mg/mL acepromazine, 1.9 mg/mL xylazine 
and 37.5 mg/mL ketamine in sterile saline at a dose of 1.5 mg/kg.  To maintain the 
anesthetic plane throughout the experiment an incomplete anesthetic cocktail was used 
containing 0.37 mg/mL acepromazine and 37.5 mg/mL ketamine at 1/3 of the initial dose 
every hour.  Once anesthetized, the rat was placed on a warming pad to maintain a body 
temperature of 37 degrees C.  Briefly, an incision was made at the neck of the animal and 
the salivary gland, sternohyodious and sternomastoideus muscles were moved to expose 
the carotid artery.  The external carotid artery and occipital artery were tied off with a 
suture while the internal carotid artery was clamped.  Once the internal carotid artery was 
cannulated, the clamp was removed and perfusion buffer containing 10 µM TH-237A and 
trace amounts of [3H]-TH-237A was perfused for 60 seconds with a 30 second pre-
perfusion and 10 second post-perfusion of blank saline.  Following perfusion, the animal 
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was decapitated by guillotine and the brain was removed and placed on ice.  The brain 
was then dissolved in Solvable® for approximately 24 hours before analysis by liquid 
scintillation counting.  Animals were used and housed in accordance with The University 
of Kansas Institutional Animal Care and Use Committee’s policies.  The blood brain 
barrier transfer coefficient for unidirectional uptake of TH-237A into the brain from the 
perfusion buffer was calculated using the following equation: 
 
Kin = (Qbr/Cpf)/t 
 
where Qbr is the total amount of drug in the brain, Cpf is the concentration of drug in the 
perfusion buffer and t is the perfusion time.  Kin can then be converted into the 
cerebrovascular permeability-surface area product (PA) by using the Crone-Renkin 
model of capillary  transfer (Crone and Levitt, 1984): 
 
PA = -F ln (1 – Kin/F) 
 
Where F is the regional cerebral blood flow which was previously determined by using 
the flow limited diffusion marker [3H]-diazepam and A is the rat brain capillary surface 
area of 130 cm2/g as previously reported (Crone and Levitt, 1984).  P is the apparent 
permeability coefficient of the blood brain barrier for the test compound. 
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3.3 Results 
 
3.3.1 Effects of TH-237A on rhodamine 123 uptake 
 
TH-237A was tested in the rhodamine 123 uptake assay using BBMECs grown in a 24-
well plate.  The uptake of rhodamine 123 was monitored in the presence of TH-237A at 
concentrations ranging from 1 to 50 µM (Figure 3.3.1).  No significant increase in 
rhodamine 123 was observed, except for in the presence of the positive control, 
cyclosporine A (CsA), a known substrate for P-gp.  These data suggest TH-237A is not 
recognized as a substrate for the efflux transporter P-glycoprotein, which is expressed at 
the brain endothelium, and can present a barrier to brain penetration. 
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Figure 3.3.1.  TH-237A tested at a range of concentrations in the rhodamine 123 uptake 
assay, a surrogate measure of P-gp interaction. (** Denotes p<0.01 compared to the 
control (rhodamine alone) as determined by ANOVA, Data ± SD, n=3) 
** 
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3.3.2 Bi-directional permeation of TH-237A across BBMEC monolayers 
 
TH-237A (10 µM) was added to the luminal (blood) or abluminal (brain) side of the 
BBMEC monolayer and permeation was monitored for 1.5 hours.  During this time, 
permeation across the monolayer was linear (R2= 0.99) and all experiments were carried 
out N=4.  The apparent permeability value of TH-237A was calculated using the 
following equation:  
 
Papp =  (∆Q/∆t)/ A x C0 
 
where ∆Q/∆t is the linear appearance of TH-237A in the receiver chamber, A is the cross 
sectional area of the cell monolayer (0.636 cm2) and C0 is the initial concentration of TH-
237A in the donor chamber at t = 0.  In the luminal to abluminal direction, the Papp = 2.86 
x 10-4 cm/sec and in the abluminal to luminal direction, the Papp = 2.44 x 10
-4 producing 
no statistically significant difference in permeability as a result of direction (Figure 
3.3.2).   
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Figure 3.3.2.  Bi-directional permeability data for TH-237A in BBMECs.  No statistical 
difference was observed.  (Data ± SD, n=8)   
 
 
3.3.3 Temperature-dependent permeation of TH-237A across BBMEC monolayers 
 
Permeation of TH-237A was investigated at a range of temperatures in order to generate 
an Arrhenius plot.  The permeability of TH-237A was calculated in the luminal to 
abluminal direction at temperatures of 4, 8, 12, 16, 20, 26, 30 and 37 degrees C.  The 
activation energy calculated from the slope of the Arrhenius plot is 26.3 kJ/mol, 
suggestive of a passive process (Figure 3.3.3). 
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Figure 3.3.3. Arrhenius plot generated by the temperature dependent permeability of TH-
237A in BBMECs.  Permeability values were calculated at a variety of temperatures 
ranging from 4 degrees C to 37 degrees C. (Data ± SD, n=4) 
 
3.3.4 Inhibition studies using [
3
H]-TH-237A 
 
The uptake of [3H]-TH-237A into BBMECs was measured in the presence of varying 
amounts of unlabeled TH-237A.  There was no significant difference in [3H]-TH-237A 
uptake in the presence of small amounts, equal amounts nor excess amounts of unlabeled 
TH-237A, further suggesting that the uptake of the compound into the cells was passive 
diffusion (Figure 3.3.4). 
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Figure 3.3.4.  The intracellular uptake of [3H]-TH-237A in the presence of increasing 
concentrations of unlabeled TH-237A. (no statistical difference from control, Data ± SD, 
n=3) 
 
 
 3.3.5 In situ rat brain perfusion 
 
Brain penetration of TH-237A was investigated using the in situ rat brain perfusion 
modeled described by Smith and Allen (Smith and Allen, 2003).  A solution of 10 µM 
TH-237A containing trace amounts of [3H]-TH-237A was infused into the carotid artery 
of cannulated rats for 60 seconds.  A pre-wash infusion of saline was performed for 30 
seconds and a post-wash infusion was performed for 10 seconds before harvesting the 
brain.  Solubilized brain tissue was then analyzed by liquid scintillation counting.  The 
blood brain barrier transfer coefficient (Kin) for unidirectional uptake of TH-237A was 
determined to be 3.87 x 10-3 mL/s/g where Qbr =2.32 nmol/g, Cpf = 10.01 nmol/mL and 
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t= 60 sec.  The Kin was converted to the cerebrovascular permeability-surface area 
product (PA) using a regional cerebral flow of 0.0253 mL/s/g and an area = 130 cm2 to 
give an apparent permeability coefficient of the blood brain barrier for TH-237A = 3.23 x 
10-5 cm/sec (Figure 3.3.5).  For comparison purposes, the permeability of sucrose, a low 
permeability, paracellular marker, was determined as well as that of paclitaxel which is a 
pharmaceutical agent known to have very minimal brain penetration.  Sucrose and 
paclitaxel had apparent permeability coefficients of 7.43 x 10-6 cm/sec and 1.70 x 10-7 
cm/sec respectively. 
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Figure 3.3.5.  Apparent permeability coefficients of TH-237A, sucrose and paclitaxel as 
determined using the in situ rat brain perfusion model. (Data ± SD, n=3). 
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3.4 Discussion 
 
Like paclitaxel, GS-164 is a microtubule stabilizing compound that has been shown to be 
both chemotherapeutic and neuroprotective.  A variety of isomers of GS-164 were 
synthesized and TH-237A, the cis-isomer of GS-164, has been shown to have excellent 
neuroprotective properties, but is only mildly chemotherapeutic (data not shown).  Since 
TH-237A must be able to cross the blood brain barrier to exert its neuroprotective effects, 
the potential for TH-237A to penetrate the blood brain barrier was thoroughly 
investigated in vitro, in situ and in vivo.  In vitro studies performed using BBMECs as a 
model of the blood brain barrier indicated that TH-237A had excellent potential for brain 
penetration and this was confirmed with in situ and in vivo studies.  Although TH-237A 
is a microtubule stabilizing agent like paclitaxel, it is structurally very different.  The 
physicochemical properties of TH-237A make it a much better candidate for use as a 
CNS drug.  Compared to paclitaxel, TH-237A has a much lower molecular weight (MW: 
333.3), possesses halogen groups that improve passive diffusion and is not a substrate for 
any of the efflux transporters expressed at the brain endothelium.   All of these features 
are very important in determining whether a drug will be able to cross the blood brain 
barrier and reach a site of action within the brain (Birnbaum, 1985; Mahar Doan et al., 
2002; Raub, 2006). 
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3.5 Conclusion 
 
Studies suggesting that microtubule stabilizing compounds can be neuroprotective 
against the effects of Aβ induced neurodegeneration prompted our collaborators in the 
Department of Pharmacology and Toxicology to examine the effect of various taxane 
molecules as well as structurally diverse microtubule stabilizing compounds in an in vitro 
neuronal survival assay.  Since neuroprotection was observed with paclitaxel and several 
of its derivatives (Michaelis et al., 2005), we investigated GS-164, a small molecule 
purported to bind microtubules in a similar fashion as paclitaxel.  In addition to GS-164, 
pure stereoisomers of GS-164 were also tested.  The cis-isomer, TH-237A, was seen to 
have excellent neuroprotective properties as well as excellent penetration across the 
blood brain barrier, making it an excellent candidate for a neuroprotective agent.  In vitro 
studies indicated that TH-237A crosses the blood brain barrier in a passive fashion and in 
vivo studies demonstrated that brain uptake was rapid and the drug remained in the brain 
for a prolonged time, with a half-life on the order of hours.   
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Chapter 4:  TCP-FA4: A Derivative of Tranylcypromine Exhibiting Improved 
Blood Brain Barrier Permeability 
 
4.1 Introduction 
 
Delivery of pharmaceutical agents to the brain is one of the most challenging areas of 
drug delivery.  The biological makeup of the blood brain barrier creates a very 
formidable barrier.  Tight junctions, minimized surface area, electrostatics and increased 
metabolism as well as efflux systems all work together to create this barrier (Reese and 
Karnovsky, 1967; Brightman and Reese, 1969; Hegmann et al., 1992; Huai-Yun et al., 
1998).  A variety of approaches have been taken to improve the brain penetration of 
pharmaceutical agents, some of which have been outlined in previous chapters of this 
dissertation.  The objective of this specific study was to investigate the effect of the 
attachment of lipoamino acids and fatty acid chains on the blood brain barrier 
permeability of a model compound, tranylcypromine.  This project was in collaboration 
with colleagues at the Dipartimento de Scienze Farmaceutiche at Univerità degli Studi di 
Catania in Catania, Italy. 
 
The rationale behind this study was that by increasing the membrane-like character of a 
compound, one can improve it’s interaction with the lipid bilayer within cell membranes, 
and as a result improve permeability.  The proof of concept was attempted using the 
irreversible monoamine oxidase inhibitor (MAOI) tranylcypromine (TCP) (Figure 4.1).  
Various derivatives of TCP were synthesized by our collaborators at the Univerità degli 
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Studi di Catania in which fatty acid chains or lipoamino acids of various lengths were 
attached (Pignatello et al., 2005) (Figure 4.2).   
 
 
 
 
 
Figure 4.1 Tranylcypromine an irreversible MAO inhibitor 
NH2
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Compound n 
TCP-LAA6 3 
TCP-LAA10 7 
TCP-LAA12 9 
 
 
 
 
 
 
Compound n 
TCP-FA4 2 
TCP-FA12 10 
 
 
Figure 4.2 Tranylcypromine derivatives of lipoamino acids (LAA) or fatty acids (FA) of 
varying length. 
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Although the addition of fatty acid chains increases lipophilicity, the addition of 
lipoamino acids has the added advantage of incorporating amphipathic character into the 
drug molecules which in turn can facilitate their interaction with cell membranes.  This 
approach to improving permeability across biological barriers, including the blood brain 
barrier, has been taken before and has shown some success (Jolliet-Riant and Tillement, 
1999; Bodor and Buchwald, 2002; Waterhouse, 2003).  Various approaches both 
computational and experimental were taken by our Italian collaborators to predict the 
TCP derivatives’ interaction with membranes (Pignatello et al., 2005; Pignatello et al., 
2006) (data not included).  These TCP derivatives were then tested in our laboratory 
using an in vitro model of the blood brain barrier in which we use bovine brain 
microvessel endothelial cells (BBMECs).  Studies showed that although TCP derivatives 
containing lipoamino acids were predicted to have better permeability than their fatty 
acid counterparts, TCP-FA4, one of the derivatives containing a four carbon fatty acid 
chain showed the greatest improvement in permeability.  The transport properties of this 
derivative were thoroughly characterized and are described herein. 
 
Furthermore, we briefly investigated the neuroprotective properties of TCP-FA4.  
Although this compound was originally synthesized as a model compound to demonstrate 
a proof of concept, literature suggested that tranylcypromine could have neuroprotective 
properties (Sowa et al., 2004).  Since TCP-FA4 is predicted to have such excellent blood 
brain barrier permeability, it could prove to be an important discovery if it is 
neuroprotective.  TCP (and potentially its derivatives) could be neuroprotective as a 
result of their ability to induce synthesis of brain derived neurotrophic factor (BDNF) 
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(Sowa et al., 2004).  BDNF is a 27 kDa protein found within the brain and periphery that 
supports the survival of existing neurons as well as aids in the growth and differentiation 
of new neurons (Pezet and Malcangio, 2004).  In recent years, BDNF has become a drug 
target for many CNS disorders including Alzheimer’s, Parkinson’s, epilepsy, (Pezet and 
Malcangio, 2004) as well as cerebral ischemia (Sowa et al., 2004).  Since neurotrophins 
possess less than optimal pharmacological properties including poor stability and 
minimal blood brain barrier permeation, the discovery of small molecules that can 
regulate BDNF expression could prove beneficial (Longo and Massa, 2005).   
 
4.2 Experimental 
 
4.2.1 Isolation and maintenance of BBMECs 
 
Bovine brain microvessel endothelial cells (BBMECs) were isolated from the gray matter 
of bovine cerebral cortices by enzymatic digestion followed by centrifugation and then 
seeded as primary cultures following methods described by Audus et al. (Audus and 
Borchardt, 1987). Isolated BBMECs were seeded at a density of approximately 50,000 
cells/cm2 onto 24-well culture plates or 100 mm culture dishes (Corning Costar, Acton, 
MA) containing Nucleopore® polycarbonate membranes (pore size 0.4 µm) (Whatman, 
Florham Park, NJ) pretreated with rat-tail collagen prepared in house and fibronectin 
(Sigma-Aldrich, St. Louis, MO).  Culture medium was prepared and cells were 
maintained as described in the experimental section of Chapter 2.  
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4.2.2 Maintenance of HUVECs 
 
Human umbilical vein endothelial cells (HUVECs) were obtained from American Type 
Culture Collection (ATCC) (Manassas, VA) and cultured in Dulbecco’s modified eagle’s 
media containing 10% fetal bovine serum, 100 units/mL of penicillin G sodium, 100 
µg/mL of streptomycin sulfate, 2.0 g/L NaHCO3, 1.42 g/L HEPES-Na, 1% glutamine, 
and 1% nonessential amino acids.  Cell culture medium was replaced every other day 
after seeding until cells had grown to confluency.  Cells were grown at 37 degrees C 
under 5% CO2 and 95% relative humidity.   
 
4.2.3 Rhodamine 123 uptake assay 
 
Although tranylcypromine is not known to be a substrate for any efflux transporters 
expressed at the brain endothelium, the TCP derivatives were tested for potential 
interaction with P-glycoprotein (P-gp), one of the most prevalent of the efflux 
transporters that is most responsible for limiting drug entry into the brain (van Asperen et 
al., 1997).  Since these molecules had increased lipophilicity, there was a chance they 
could become substrates since P-gp substrates are often lipophilic in nature (Stouch and 
Gudmundsson, 2002).   The rhodamine 123 assay is a rather facile and reliable way to 
predict potential P-gp interaction  (Fontaine et al., 1996).  The effect of the test 
compound on rhodamine123 is determined by monitoring intracellular fluorescence.  If 
the test compound is a substrate for P-gp, then addition of the compound will increase 
rhodamine 123 uptake relative to the negative control.  BBMECs were seeded onto 
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24-well plates coated with rat tail collagen and fibronectin at a density of approximately 
50,000 cells/cm2.  Culture medium was replaced every other day until cells formed a 
confluent monolayer.  At the start of the experiment, BBMECs were rinsed with warm 
PBSA (PBS containing CaCl2, MgSO4, glucose and L-ascorbic acid) and allowed to 
acclimate to the warm PBSA for 10 minutes.  The PBSA was removed and solutions of 
TCP derivatives (conc.: 10 µM) were added to the wells and allowed to incubate for 30 
minutes at 37 degrees C in a hotbox. Rhodamine 123 was then added to all wells at a 
concentration of 5 µM and the plate was returned to the hotbox.  Cells were incubated for 
an additional 2 hours.  After the incubation, cells were quickly rinsed with ice cold PBS 
several times.  Lysis buffer (0.5% v/v Triton X-100 in 0.2N NaOH) was then added to all 
wells and allowed to solubilize cells for at least 30 minutes.  200 µL aliquots were taken 
from all wells to determine Rhodamine 123 concentration and 10 µL aliquots were taken 
from all wells to determine protein concentration.  Rhodamine 123 concentrations were 
determined on a Biotek FL600 Microplate Fluorescence Reader (excitationλ: 485, 
emissionλ: 530).  Protein determination was performed using a Pierce BCA Protein 
Assay Kit (Pierce, Rockford, IL) and samples were read on an EIA reader at 540 nm. 
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4.2.4 Characterization of TCP derivative transport using BBMEC monolayers 
 
4.2.4.1 Permeability studies 
 
BBMECs were grown on 0.4 µm Nucleopore® polycarbonate membranes in a 100 mm 
culture dish coated with rat tail collagen and fibronectin.  Once cells had formed a 
confluent monolayer as determined by light microscopy, the membranes were transferred 
to Side-bi-Side™ diffusion chambers as previously described by Audus et al. (Audus et 
al., 1996; Audus et al., 1998).  Briefly, each chamber was filled with 3mL of PBSA and 
the luminal donor chamber contained 10 µM of the TCP derivative.  A temperature of 37 
degrees C was maintained within the chamber with an external circulating water bath and 
chamber contents were stirred with Teflon coated magnetic stir bars driven by an external 
console.   At the various time points (5, 15, 30, 45 and 90 minutes), 200 µL aliquots were 
removed from the receiver side and replaced with 200 µL of blank PBSA warmed to 37 
degrees C.  For the derivative TCP-FA4, permeability was extremely rapid, so in order to 
monitor permeability within a linear range, earlier timepoints had to be taken.  For all 
studies with TCP-FA4, timepoints were instead taken at 2, 5, 10, 15, 20 and 30 minutes. 
Samples of the donor solution were also taken for analysis.  All samples were analyzed 
for concentration using LC/MS/MS analysis (see section 4.2.4.5 for details).    The 
integrity of the cell monolayer was tested post experiment by monitoring the permeability 
of [14C]-sucrose, a paracellular marker which should not readily cross the cell monolayer.  
All sucrose samples were analyzed for concentration by liquid scintillation counting. 
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Additionally, this same experimental setup was used to investigate whether there were 
any directional differences in transport due to membrane transporters.  In these bi-
directional permeability studies, compound was added to the abluminal side and the 
luminal side was monitored over time. 
 
4.2.4.2 TCP-FA4: Temperature dependent permeation studies  
 
Again, BBMECs were grown on 0.4 µm Nucleopore® polycarbonate membranes then 
transferred to Side-bi-Side™ diffusion chambers. 10 µM of TCP-FA4 was added to the 
luminal chambers and 200 µL samples were taken from the abluminal chamber at various 
time points (2, 5, 10, 15, 20 and 30 minutes) and analyzed by LC/MS/MS.  Permeation of 
TCP-FA4 was calculated at a range of temperatures (4, 8, 16, 23, 30 and 37 degrees C) in 
order to determine an activation energy.  The integrity of the cell monolayer was tested 
post experiment by monitoring the permeability of [14C]-sucrose and samples were 
analyzed by liquid scintillation counting.   
 
4.2.4.3 TCP-FA4: Inhibition studies  
 
Inhibition studies were performed to determine if permeation of TCP-FA4 was an active 
process.  Inhibitors used included 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS) 
an anion-exchange inhibitor, ouabain, a sodium pump blocker (Na-K-ATPase), sodium 
azide, a metabolic inhibitor capable of depleting ATP and carbonyl cyanide 
p-(trifluoromethoxy)phenylhydrazone (FCCP), an ionophore inhibitor.  Inhibitor 
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concentrations and treatment conditions were decided upon based on prior studies 
performed in the laboratory (Utoguchi et al., 1999).  BBMECs were grown on 0.4 µm 
Nucleopore® polycarbonate membranes in a 100 mm culture dish coated with rat tail 
collagen and fibronectin at a density of approximately 50,000 cells/cm2.  Upon 
confluency, cells were washed several times with warm PBSA and allowed to acclimate.  
Cells were then mounted in Side-bi-Side™ chambers and TCP-FA4 permeability was 
monitored in the presence of the various inhibitors.  Aliquots were taken from the 
receiver chamber at 2, 5, 10, 15, 20 and 30 minutes.   
 
4.2.4.4 Measurement of BDNF with enzyme-linked immunosorbent assay (ELISA) 
 
To determine if TCP-FA4 can increase the production of brain derived neurotropic factor 
(BDNF), analysis of cell culture media post treatment with TCP-FA4 was performed.  
Initially, BBMECs were used for these studies; however, there was no existing literature 
confirming that BBMECs grown in culture synthesize or secrete BDNF.  Our studies 
showed that in fact BBMECs do not secrete detectable levels of BDNF (detection limit: 
15.6 pg/mL).  Therefore, another cell culture system had to be used and, based on studies 
by Nakahashi et al., it was seen that human umbilical vein endothelial cells (HUVECs) 
synthesize and secrete BDNF (Nakahashi et al., 2000). HUVECs were grown to 
confluency in a 6-well tissue culture plate (approximately 5 days) then washed three 
times with phosphate buffered saline warmed to 37 degrees C.  Solutions of 5 µM TCP 
and 5 µM TCP-FA4 were prepared in culture media and added to the wells (N=2).  The 
remaining two wells contained blank media and served as a control.  Aliquots of 200 µL 
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were taken from the wells at 0, 24, 31 and 48 hours and stored at – 20 degrees C until 
analysis.  Prior to analysis samples were centrifuged at 4 degrees C at 1500 x g to remove 
any particulates.  Concentrations of BDNF were measured using a commercial ELISA kit 
(Promega, Madison, WI).  For optimal results, all samples were diluted 1:1 with the 
provided Block & Sample Buffer.  A standard curve was created and linearity (R2 = 0.99) 
was observed from 7 to 250 pg/mL (Figure 4.2.4.4.1).  According to the manufacturer’s 
brochure, the assay provides specific detection of BDNF with typically less than 3% 
cross reactivity with other related neurotrophic factors and provides a lower detection 
limit of 15.6 pg/mL. 
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Figure 4.2.4.4.1 Representative calibration curve for the BDNF immunoassay showing 
linearity over a range of 7 – 250 pg/mL. (Data ± SD, n=4) 
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4.2.4.5 Sample analysis of TCP and derivatives by LC/MS/MS 
 
Samples generated by the permeability studies using BBMECs were analyzed by 
LC/MS/MS.  The chromatography system consisted of a Waters 2690 system and a 
Phenomenex Onyx monolithic C18 column (50 x 4.6 mm). After chromatographic 
separation, samples were directed into the mass spectrometer (Micromass™ triple 
quadrupole) and detected by tandem mass spectrometry in positive ion mode using 
electrospray ionization.   
 
A method was adapted from Kirchher et al. (Kirchherr and Kuhn-Velten, 2005) that 
included an isocratic HPLC method using a mobile phase of acetonitrile/5mM acetic 
acid, pH 3.9 with ammonia.  The ratio of aqueous to organic was modified slightly based 
on the lipophilicity of the derivative and ranged from 10:90 (v/v) acetonitrile: 5 mM 
acetic acid to 50:50 (v/v) acetonitrile: 5 mM acetic acid.  A diversion of the HPLC eluent 
between 0 and 2 minutes reduced the exposure of the mass spectrometer to possible salts 
and cellular contaminates in the sample.  Based on the mobile phase ratios and the 
lipophilicity of the derivatives, the retention times shifted appropriately (Figure 
4.2.4.5.1). 
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Figure 4.2.4.5.1 Representative MS chromatograms of tranylcypromine and two 
derivatives, TCP-FA4 and TCP-LAA6, demonstrating the slight shifts in retention time 
based on isocratic method and the changes in lipophilicity.  All chromatograms represent 
total ion current (TIC).  Structures found on page 103. 
 
 
To select the optimal product-ions for analysis, solutions of tranylcypromine and the 
various derivatives, made in acetonitrile/5 mM acetic acid, pH 3.9 with ammonia (10:90, 
v/v), were first infused into the mass spectrometer and fragmentation patterns were 
monitored and parameters were optimized.  Tranylcypromine and its derivatives were 
chromatographed and detected using multiple reaction monitoring.  For tranylcypromine 
the m/z 134  m/z 117 transition was monitored (Figure 4.2.4.5.2).  The derivatives 
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fragmented such that there was cleavage at the added fatty acid or lipoamino acid groups 
giving tranylcypromine as a daughter ion as well as the m/z 117 daughter ion (Figure 
4.2.4.5.3).   
 
 
 
 
Figure 4.2.4.5.2 Electrospray ionization (ESI)-MS/MS (positive ion mode) product-ion 
spectra of tranylcypromine (m/z 134) 
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Figure 4.2.4.5.3 Electrospray ionization (ESI)-MS/MS (positive ion mode) product-ion 
spectra of a representative derivative of tranylcypromine, TCP-LAA6 (m/z 247).  
Structure found on page 103. 
 
 
Standards generated showed good linearity over a calibration range of 10-1000 ng/mL 
and this was consistent for the various derivatives as well.  Standard curves for TCP-FA4 
were extended to include concentrations up to 5000 ng/mL, and good linearity was still 
maintained.  Figure 4.2.4.5.4 is a calibration curve for tranylcypromine and Figure 
4.2.4.5.5 is a representative calibration curve of one of the tranylcypromine derivatives 
(TCP-FA4), showing linearity was achieved for the derivatives as well. 
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Figure 4.2.4.5.4 Calibration curve of tranylcypromine.  Linearity was seen from 5 – 1000 
ng/mL. 
 
 
 
 
Figure 4.2.4.5.5 Representative calibration curve of a tranylcypromine derivative (TCP-
FA4).  Linearity was seen from 5 – 5000 ng/mL. 
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4.3 Results 
 
4.3.1 Rhodamine 123 uptake assay 
 
Tranylcypromine is not a known substrate for any of the efflux transporters expressed at 
the blood brain barrier, but once lipophilicity is increased, the likelihood that the 
compounds could become substrates increases.  Therefore, we tested the various 
derivatives for potential P-gp interaction which is one of the most prevalent of the efflux 
transporters.  Results from the rhodamine 123 uptake assay suggest that none of the 
derivates were interacting with P-gp (Figure 4.3.1.1).  All compounds were tested at a 
concentration of 10 µM and only the positive control showed any effect on intracellular 
rhodamine 123 uptake. 
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Figure 4.3.1.1 Rhodamine 123 uptake assay results suggest that the TCP derivatives do 
not interact with the efflux protein, P-gp. (** Denotes p<0.01 compared to control 
(rhodamine alone) as determined by ANOVA, Data ± SD, n=3).  Structures found on 
page 103. 
 
4.3.2 Permeability studies in BBMECs 
 
The permeability of tranylcypromine and its derivatives was calculated using BBMEC 
monolayers mounted in Side-bi-Side™ chambers.  The apparent permeability values 
were calculated using the following equation:  
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where ∆Q/∆t is the linear appearance of the test compound in the receiver chamber, A is 
the cross sectional area of the cell monolayer (0.636 cm2) and C0 is the initial 
concentration of the test compound in the donor chamber at t = 0.  Tranylcypromine had 
a permeability of approximately 2.9 x 10-4 cm/sec and TCP-FA4, a derivative containing 
a fatty acid side chain, showed an improved permeability of 3.8 x 10-4 cm/sec.  The 
derivatives containing the lipoamino acid groups did not show an improvement in 
permeability relative to tranylcypromine and those derivatives with the longest fatty acid 
and lipoamino acid groups (TCP-FA12 and TCP-LAA12) were below the limit of 
detection (Figure 4.3.2.1).  Sucrose values for these studies ranged from 2.0 x 10-5 cm/sec 
to 7 x 10-5 cm/sec.  
 
 
 
 
 
 
 
 
 
Figure 4.3.2.1 Permeability of tranylcypromine and its derivatives in BBMECs.  TCP-
FA12 and TCP-LAA12 were below the limit of detection.  (** Denotes p<0.01 compared 
to TCP as determined by ANOVA, Data ± SD, TCP and TCP-FA4 n=8, TCP-LAA6 and 
TCP LAA10 n=4).    Structures found on page 103. 
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4.3.3 Bi-directional permeability study of TCP-FA4 
 
To determine if TCP-FA4’s improved permeability was due to an uptake transporter, the 
percentage of TCP-FA4 transported over time across a BBMEC monolayer was 
monitored in both the luminal to abluminal and abluminal to luminal directions.  Studies 
indicated that there was a slight decrease in permeability going from the abluminal to 
luminal side (Figure 4.3.3.1).  The apparent permeability of TCP-FA4 in the luminal to 
abluminal direction had an average Papp = 5.47 x 10
-4 cm/sec (std dev: 2.4 x 10-5 cm/sec) 
and in the abluminal to luminal direction a Papp =  4.38 x 10
-4 cm/sec (std dev: 1.4 x 10-5 
cm/sec).  To determine if this difference was in fact due to some sort of uptake or 
facilitative process, additional temperature dependent and inhibition studies were 
performed. 
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Figure 4.3.3.1 Percentage of TCP-FA4 transported over time in the luminal to abluminal 
and abluminal to luminal directions.  (Data ± SD, n=8) 
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4.3.4 Temperature dependent permeability studies of TCP-FA4 
 
The permeability of TCP-FA4 was monitored at a range of temperatures such that an 
activation energy of transport could be calculated.  Studies were performed using 
BBMEC monolayers mounted in Side-bi-Side™ chambers.  An Arrhenius plot was 
generated by plotting 1/ T versus the natural log of the apparent permeability values and 
the activation energy of transport was determined to be 28.0 kJ/mol (Figure 4.3.4.1). 
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Figure 4.3.4.1 Arrhenius plot generated by the temperature dependent permeability of 
TCP-FA4 in BBMECs.  Permeability values were calculated at a variety of temperatures 
ranging from 4 degrees C to 37 degrees C. (Data ± SD, n=4, except 4 and 37 degrees C, 
n=8) 
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4.3.5 TCP-FA4: Inhibition studies  
 
The effect of various inhibitors on the permeability of TCP-FA4 was investigated (Figure 
4.3.5.1).  For all inhibition studies, BBMECs were pretreated with agents for 15 minutes 
prior to performing the permeability study.  Ouabain octahydrate, a sodium pump 
blocker, was used to determine if the permeability of TCP-FA4 was a sodium coupled 
process.  Permeability of TCP-FA4 was monitored in the presence of 100 µM ouabain, 
but no significant changes in permeability were noted.  Sodium azide, a respiratory chain 
inhibitor, was used as a metabolic inhibitor to investigate if the transport of TCP-FA4 
was via a process that required cell-dependent energy expenditure.  However, the 
permeability of TCP-FA4 did not decrease in the presence of 10 mM sodium azide.  
FCCP, a protonophore, was used to determine if the permeability of TCP-FA4 would be 
altered upon disruption of the proton gradient, but at a final concentration of 50 µM 
FCCP no changes in TCP-FA4 permeability were noted.  Furthermore, in the presence of 
50 µM DIDS, an anion-exchange inhibitor, no changes in TCP-FA4 permeability were 
observed.  These studies suggested that the permeation of TCP-FA4 was most likely a 
passive process and was neither an active nor facilitative process.  
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Figure 4.3.5.1 Effects of various inhibitors on the transport of TCP-FA4 in BBMECs. 
(Data ± SD, n=4) 
 
4.3.6 BDNF production by HUVECs in the presence of TCP-FA4 
 
The effect of TCP-FA4 on the production of BDNF in HUVECs was investigated.  
HUVECs were treated with 5 µM TCP-FA4 to determine if the derivative was capable of 
increasing production of BDNF relative to tranylcypromine.  Results showed an increase 
in BDNF production relative to the control (blank media) as well as tranylcypromine.  
Levels of secreted BDNF increased over time and were highest when treated with TCP-
FA4.  At 48 hours post treatment with TCP-FA4, BDNF was detected at 122.6 ± 1.9 
pg/mL, compared to 101.8 ± 4.6 and 92.3 ± 2.1 pg/mL for TCP and blank media 
respectively (n = 4) (Figure 4.3.6.1) 
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Figure 4.3.6.1 BDNF secretion by cultured HUVECs in the presence of TCP and TCP-
FA4. (** Denotes p<0.01 compared to control as determined by ANOVA, Data ± SD, 
n=4) 
 
4.4 Discussion 
 
Derivatives of tranylcypromine containing fatty acid and lipoamino acid chains of 
varying length were synthesized in an attempt to improve the blood brain barrier 
permeability by increasing the lipophilicity as well as amphiphatic character of the 
molecule.  Our collaborators investigated the altered lipophilicity of these derivatives by 
calculating the log P as well as the partition coefficient between the blood and brain (log 
BB) using the software programs ACD log P 5.15, Pallas 3.0, Osiris Property Explorer 
and KOWIN 1.57.  Results suggested that lipoamino acid promoieties containing medium 
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to long side alkyl chains would be most useful in improving the permeability and 
membrane interaction of these compounds (Pignatello et al., 2006).  Additionally, studies 
using multilamellar vesicles and dimyristoylphosphatidylcholine (DMPC) monolayers as 
biomembranes models confirmed these results (Pignatello et al., 2006).  However, when 
using BBMECs as a model for the blood brain barrier, the fatty acid derivative TCP-FA4 
showed the greatest improvement in permeability.  This derivative contained a four 
carbon fatty acid chain and had an approximate 2 fold increase in lipophilicity over the 
parent compound (Pignatello et al., 2005).  The permeability results for this compound 
indicated that TCP-FA4 had good passive permeability and was not a substrate for any 
active transport systems expressed in the BBMECs.  Furthermore, the utility as a 
pharmaceutical agent of a tranylcypromine derivative possessing improved permeability 
was investigated.  Our collaborators investigated the activity of this derivative as an 
MAO inhibitor. Although it was found that TCP-FA4 does exhibit inhibitory activity 
against MAO enzymes, its affinity was reduced compared to the parent compound, 
tranylcypromine (data not yet published).    However, our studies indicate that TCP-FA4 
may possess neuroprotective properties.  In a β-amyloid induced neurodegeneration 
assay, neurons exposed to β-amyloid in the presence of 200 nM TCP-FA4 showed a 20% 
improvement in survival rate (data not shown).  Additionally, using HUVECs grown in 
culture, increased levels of the neurotrophic factor BDNF were observed in the presence 
of TCP-FA4.  Since BDNF is instrumental in the survival and differentiation of neurons 
and BDNF expression is altered in many brain disorders, the discovery of small 
molecules capable of regulating BDNF may be beneficial.       
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4.5 Conclusion 
 
TCP-FA4, is a derivative of the MAO inhibitor tranylcypromine containing a fatty acid 
chain to enhance lipophilicity, which is predicted to have improved blood brain barrier 
permeability based on in vitro studies using BBMECs.  This molecule has also been 
shown to be a potential neuroprotective agent.  In addition to its favorable 
physicochemical properties, it has been shown to be slightly neuroprotective in a β-
amyloid induced neurodegeneration assay and may also be capable of upregulating the 
neurotrophic factor BDNF as indicated by cell culture assays using HUVECs.  Since 
decreased levels of BDNF are observed in many CNS disorders, and direct injection of 
BDNF is not a viable option due to its poor permeability across the blood brain barrier, 
small molecules capable of regulating BDNF that also cross the blood brain barrier may 
be a treatment option (Longo and Massa, 2005). 
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Chapter 5: Summary and Future Direction 
 
Drug delivery to the brain is often challenging and with an aging population brain 
disorders are becoming a major problem (Riggs, 1998).  Alzheimer’s, Parkinson’s and 
conditions such as cerebral ischemia in stroke are all prevalent diseases in an aging 
population, which currently have no cure.  Investigating therapeutics which address these 
unmet medical needs is very important.  In order for CNS therapeutics to be effective, 
they must be able to penetrate the blood brain barrier and reach their site of action.  
Therefore, understanding ways to improve a molecule’s blood brain barrier permeability 
becomes essential in developing more effective CNS drugs.  There are a variety of 
approaches to improving blood brain barrier permeability, a select few which have been 
discussed within this dissertation.   
 
Paclitaxel is a chemotherapeutic compound that has been successfully used for a variety 
of cancers, but cannot be used to treat brain cancer because it does not cross the blood 
brain barrier (Fellner et al., 2002).  In the case of paclitaxel, the drug is a substrate for an 
efflux transporter expressed at the brain endothelium.  To improve the blood brain barrier 
permeability in a case in which drug efflux is a problem, one approach is to structurally 
modify the drug such that is retains its chemotherapeutic effect but is no longer a 
substrate for the efflux transporter.  GS-164 is a molecule that has been shown to be both 
chemotherapeutic and neuroprotective.  To optimize this compound’s success as a 
chemotherapeutic or neuroprotective agent, a variety of stereoisomers were synthesized 
and the cis-isomer TH-237A was shown to have excellent neuroprotective properties.  
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This is an example of taking a molecule that has inherently good physicochemical 
properties that make it a good candidate for a CNS drug and evaluating slight structural 
changes to make it the most effective as a neuroprotective agent.  Another approach to 
improve the blood brain barrier penetration is to modify a compound so that it has 
enhanced lipophilicity and improve its interaction with the cell membrane.  This was 
successful in the example with tranylcypromine in which the fatty acid derivative 
TCP-FA4 showed an improvement in permeability in BBMECs over the parent 
compound. 
 
An interesting feature that is common to the molecules discussed within this dissertation 
is that they are chemotherapeutic as well as neuroprotective to varying degrees.  The 
exception being the tranylcypromine derivatives which only hold promise as being 
potential neuroprotective agents.  Derivatives of paclitaxel and GS-164 have been seen to 
have anti-proliferative effects in vitro when tested in cancer cell lines (Shintani et al., 
1997; Spletstoser et al., 2006).  Furthermore, at low concentrations they have shown to be 
neuroprotective in vitro against the β-amyloid induced neurodegeneration seen in 
Alzheimer’s disease (Michaelis et al., 2005).  These two groups of molecules are 
classified as microtubule stabilizing agents. Although their binding interactions with 
microtubules seem to vary, it may be via this interaction that they are able to provide 
neuroprotection.  The molecule A4, a small molecule novobiocin analogue, which is 
discussed within Appendix 1 also has the unique characteristic of being both 
chemotherapeutic and neuroprotective.  However, this molecule cannot be classified as a 
microtubule stabilizing compound, but rather an Hsp90 inhibitor.  Lastly, TCP-FA4, 
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showed possible neuroprotective properties with yet another possible mechanism of 
action.  Cell culture studies showed that TCP-FA4 is capable of increasing the expression 
of the neurotrophin BDNF.  BDNF has been implicated in the survival and maintenance 
of neurons in vivo. 
 
Future work on improving the blood brain barrier permeation of paclitaxel should focus 
on those structural changes that showed the greatest reduction in P-gp interaction such as 
the addition of nutrient-like groups at the C10 position and changes to the oxidation state 
of the C10 position.  Since many of our studies showed the importance of the C10 
position to P-gp’s recognition of the paclitaxel derivatives, chemistry efforts should focus 
on modification of this position.  Furthermore, the lack of improvement in permeability 
for those molecules showing a reduction in interaction in P-gp must be investigated.  
Since the substrate specificity of many of the efflux transporters overlap, it is possible 
that these newly synthesized derivatives are now substrates for efflux transporters other 
than P-gp.  Development of assays that allow researchers to tease out the contribution of 
individual transporters would be very beneficial. 
 
Studies further investigating the utility of TH-237A as a neuroprotective agent are 
ongoing.  Future studies include the in vivo effects of TH-237A in tau mutant mice.  End 
points for these studies will include progression of disease state as well as the levels of 
abnormal tau protein. 
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Furthermore, additional work could be done investigating the role of TCP-FA4 as a 
neuroprotective agent.  Preliminary studies suggest that TCP-FA4 increases levels of 
secreted BDNF in HUVECs.  Additional studies could be done to determine if this effect 
is dose dependent.  Moreover, it would be interesting to see if this increase in BDNF 
translates into a protective effect on the cells.  Cell culture studies performed in a hypoxic 
environment could mimic the stress conditions in an in vivo situation such as cerebral 
ischemia. 
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Abstract 
 The molecular chaperones have been implicated in numerous neurodegenerative 
disorders in which a defining pathology is misfolded proteins and the accumulation of 
protein aggregates. In Alzheimer’s Disease, hyperphosphorylation of tau protein results 
in its dissociation from microtubules and the formation of pathogenic aggregates. An 
inverse relationship was demonstrated between Hsp90/Hsp70 levels and aggregated tau, 
suggesting that Hsp90 inhibitors that upregulate these chaperones could provide 
neuroprotection. We recently identified a small molecule novobiocin analogue, A4 that 
induces Hsp90 overexpression at low nanomolar concentrations and sought to test its 
neuroprotective properties. A4 protected neurons against Aβ-induced toxicity at low 
nanomolar concentrations that paralleled its ability to upregulate Hsp70 expression. A4 
exhibited no cytotoxicity in neuronal cells at the highest concentration tested, 10 µM, 
thus providing a large therapeutic window for neuroprotection. In addition, A4 was 
transported across BBMECs in vitro, suggesting the compound has the ability to 
permeate the blood brain barrier in vivo. Taken together, these data establish A4, a C-
terminal inhibitor of Hsp90, as a potent lead for the development of a novel class of 
compounds to treat Alzheimer’s Disease. 
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Introduction 
The accumulation of aggregated, fibrillar proteins is a unifying characteristic of 
chronic, late-onset neurodegenerative diseases, leading to intense research on the protein 
quality control systems within cells. The accumulation of protein aggregates within or 
outside neurons is a characteristic of the two most common age-related 
neurodegenerative diseases, Alzheimer’s (AD) and Parkinson’s Disease (PD). AD is 
characterized by two distinct cytopathologies: β-amyloid (Aβ) plaques and neurofibrillary 
tangles (NFTs) (1). Normally, the microtubule-associated protein tau is expressed in the 
neuronal cytoplasm where it serves to stabilize the microtubule network in axons. In AD, 
however, tau becomes hyperphosphorylated and results in misfolded proteins that 
dissociate from microtubules and form filamentous aggregates that polymerize into NFTs 
(2). PD is characterized by the accumulation of Lewy bodies composed primarily of 
fibrillar α-synuclein (3). Other neurodegenerative diseases such as Huntington’s disease, 
amyotrophic lateral sclerosis, prion diseases, and the taupathies are also characterized by 
similar protein aggregates.      
Molecular chaperones are responsible for the conformational maturation of 
nascent polypeptides, refolding denatured and aggregated proteins, and directing the 
ubiquitination and degradation of proteins that cannot be repaired. One family of 
molecular chaperones, the heat shock proteins (Hsps), has a profound effect on critical 
cellular processes such as cell cycle regulation and apoptosis due to its diverse biological 
activities (4,5). The major Hsp, Hsp90, exerts its effects through a wide-array of co-
chaperones, partner proteins, and immunophilins, forming the major chaperone system 
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responsible for protecting cells against toxicity resulting form the accumulation of protein 
aggregates. Based on these properties, it was proposed that increased chaperone activity 
may refold aggregating proteins and have therapeutic applications for the treatment of 
neurodegenerative diseases. Recently, Greengard and coworkers demonstrated that 
increased Hsp70 and Hsp90 levels resulted in decreased tau aggregates and provided 
neuroprotection in cells expressing mutant tau that becomes hyperphosphorylated as in 
AD brain (6). Consequently, regulation of Hsp70 and Hsp90 expression levels has been 
pursued as a novel approach toward the treatment of diseases caused by protein 
aggregates.    
 Cellular stresses such as elevated temperature, abnormal pH, oxidative stress, and 
malignancy result in the denaturation of native proteins as well as the overexpression of 
molecular chaperones to refold these structures or target them for degradation via the 
ubiquitin-proteasome pathway (7-9). Upon exposure to these stresses, Hsp90 and Hsp70 
levels are increased to assist in the rematuration process. The expression of these heat 
shock proteins is tightly regulated by the transcription factor heat shock factor 1 (HSF1). 
Under normal conditions, Hsp90 forms a stable complex with HSF1 and prevents the 
transcriptional activation of the heat shock response (10). Cellular stressors result in 
destabilization of Hsp90/HSF1, the subsequent trimerization and phosphorylation of 
HSF1, and its translocation to the nucleus, where it induces Hsp expression (11,12). 
Another key protein in the Hsp90 heteroprotein complex is the co-chaperone CHIP 
(carboxyl terminus of the Hsc70-interacting protein) (13). CHIP binds Hsp70 through its 
tetratricopeptide repeat (TPR) domain and also possesses intrinsic ubiquitin ligase 
activity, suggesting a direct link between the chaperone and the ubiquitin-proteasome 
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pathway which may modulate the cellular equilibrium of protein folding and degradation 
(14).  
Previously identified inhibitors of Hsp90 include geldanamycin (GA, Fig. 1) and 
its derivatives, which bind to the N-terminal ATP binding pocket. These N-terminal 
inhibitors manifest their activity by competitive inhibition of ATP, which serves as the 
requisite source of energy for the Hsp90-mediated protein folding process. The 
concentration of N-terminal inhibitors required to induce degradation of Hsp90-
dependent client proteins is approximately equal to that needed to increase Hsp70 and 
Hsp90 levels. Unfortunately, there is a small therapeutic window for the treatment of 
neurodegenerative diseases with these molecules because cytotoxicity generally occurs at 
these concentrations. To circumvent these issues, the further development of Hsp90 
inhibitors for the treatment of neurodegenerative diseases requires the identification of 
non-toxic inhibitors that provide a large therapeutic window, but stimulate the 
dissociation of HSF1 from Hsp90 at low concentrations and penetrate the blood-brain 
barrier (BBB). A compound with such attributes could potentially regulate the refolding 
of protein aggregates, including tau, or initiate their degradation through the ubiquitin-
proteasome pathway and provide an alternative approach toward the development of 
drugs for these diseases.  
Recently, an additional ATP-binding site on the C-terminus of Hsp90 was 
elucidated and novobiocin (Fig. 1) was identified as a competitive inhibitor of ATP with 
low affinity (~ 700 µM) (15).  Elucidation of this new inhibitor and nucleotide-binding 
domain provided a novel opportunity to regulate the Hsp90-mediated protein folding 
machinery with small molecules. In an effort to prepare more efficacious inhibitors, a 
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small library of novobiocin analogues was prepared and evaluated (16). A4 induced 
Hsp90 expression at concentrations significantly lower than those needed for client 
protein degradation. Because of this finding, we proposed that A4 possessed unique 
properties that could prove useful for the treatment of neurodegenerative diseases. In this 
communication, we detail the neuroprotective effects of A4 and describe its potential 
promise as a therapeutic lead compound for the treatment of Alzheimer’s Disease. 
 
Results 
 
Synthesis of A4. In order to prepare sufficient quantities of A4 for biological testing, it 
was necessary to devise an efficient synthetic route. As shown in Scheme 1, the coumarin 
ring (2) was constructed by the condensation of commercially available benzaldehyde 1 
with glycine in the presence of acetic anhydride (17). After selective deprotection, the 
free phenol was coupled with the trichloroacetimidate of noviose carbonate (4) (18) in the 
presence of catalytic boron trifluoride etherate (19). A4 was furnished in excellent yield 
by treatment of the cyclic carbonate (5) with triethylamine in methanol, resulting in 
solvolysis of the carbonate to afford the desired product. 
 
Neuroprotective effects of A4. Treatment of embryonic primary neurons and neuronal 
cell cultures with Aβ25-35 produces distinct morphological changes and eventual cell death 
(20). Pretreatment with neuroprotective agents can reduce or abolish these effects. The 
neuroprotective effects of A4 were determined in primary neurons derived from 
embryonic rat brain exposed to Aβ (10 µM) in the presence or absence of drug for 48 h.  
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In the majority of experiments, the toxic Aβ25-35 was used to induce cell death.  However, 
a smaller number of cultures were treated with the Aβ1-42 formed in excess in AD.  In all 
cases we found that Aβ1-42 produced effects virtually identical to those of Aβ25-35, and the 
toxicity of both was dramatically inhibited in the presence of the drug.   The percentage 
of surviving neurons was determined by labeling with the fluorescent dyes calcein-AM 
and propidium iodide as previously described (21,22). The numbers of calcein-labeled 
live cells and propidium iodide-labeled dead neurons in several fields were visualized via 
fluorescence microscopy and counted as described. In our studies, treatment of primary 
cortical neurons with Aβ alone (10 µM) represented the basal level for neuronal survival. 
Pretreatment of neuronal cells with A4 prevented Aβ–induced toxicity in a dose-
dependent fashion, with an EC50 value of ~6 nM (Fig. 2). While there were minor 
neuroprotective effects associated with A4 concentrations as low as 0.5 nM, significant 
protection was not demostrated until 5 nM. Treatment of neuronal cells with A4 alone at 
20X the EC50 value (100 nM) did not result in any observed neurotoxicity.     
 
A4 up-regulates Hsp70 in neuronal cells. Inhibition of Hsp90 induces overexpression 
of both Hsp90 and Hsp70 through dissociation of Hsp90-HSF1 complexes and 
subsequent translocation of HSF1 to the nucleus (23). Induction of both Hsp90 and 
Hsp70 by GA in cultured cells was reported to result in decreased levels of aggregated 
tau and increased levels of soluble tau, indicating that Hsp90 inhibitors can reduce toxic 
tau aggregates (6). In our neuronal cultures, A4 significantly increased Hsp70 levels at 
the concentration of 0.2 µM (Figs. 3a and b).  However, concentrations of A4 as low as 
1nM also led to increases in Hsp70 levels, compared to DMSO controls, after 48 h 
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incubation.  Hsp70 induction at 0.2 µM was comparable to that seen upon treatment with 
GA at the same concentration, suggesting A4 could potentially attenuate tau aggregation 
in a manner similar to that reported for GA. In addition, incubation with higher 
concentrations of A4 (1 and 10 µM) did not significantly increase Hsp70 levels, 
suggesting that the maximal neuroprotective effects of A4 can be elicited at 
concentrations significantly lower than any potential cytotoxic effects.  
 
A4 up-regulation of Hsps does not mirror client protein degradation.  To determine 
whether A4 exhibited its neuroprotective effects via Hsp90 inhibition, A4 was incubated 
with the well-studied mutated androgen receptor (AR)-dependent prostate cancer cell 
line, LNCaP.  As reported previously, A4 induced Hsp90 at the lowest concentrations 
tested (10nM).  In contrast, degradation of the Hsp90 client proteins AR and AKT did not 
occur until 1 µM, providing a therapeutic window of ≥ 200 fold, suggesting increased 
levels of Hsps do not correlate directly with client protein degradation for inhibitors of 
the C-terminal ATP-binding pocket (16). 
 
Anti-proliferative effects of A4. For most Hsp90 inhibitors, efficacy in degrading client 
proteins, such as Her2 and Akt, in two distinct cancer cell lines, SkBr3 and MCF-7, 
correlates well with their anti-proliferative effects (24). The anti-proliferative effect of 
GA treatment in these cell lines is well established, and we confirmed almost complete 
cytotoxicity with GA at 1 µM. GA elicited dose-dependent anti-proliferation in both cell 
lines, and the IC50 values were comparable to those reported previously (18 and 133 nM, 
respectively). In contrast, A4 demonstrated no anti-proliferative effects in either cell line 
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up to 100 µM (Fig. 4a and b), a concentration well above that necessary for complete 
neuroprotection, suggesting that C-terminal inhibitors possess a mechanism of action 
distinct from GA and other inhibitors of the N-terminus. When the effects of GA and A4 
alone were examined in neuronal cells, GA induced significant cytotoxicity at 10 µM 
after 24 h (Fig. 4c). Lower concentrations of GA led to substantial cytotoxicity after 72 h 
of incubation (data not shown). In contrast, 10 µM of A4 caused no toxic effects even 
after incubation for 72 h,  clearly indicating a novel utility for C-terminal inhibitors.  
 
Transport of A4 across the blood-brain barrier. The BBB expresses high levels of P-
glycoprotein (P-gp), an efflux pump responsible for the extrusion of numerous drugs and 
other xenobiotics from cells (25). The rhodamine 123 assay is often used to predict 
whether a compound is a potential substrate for P-gp. In this assay, rhodamine 123 is 
used as a surrogate P-gp substrate. If A4 is a substrate for P-gp, then its addition will 
increase rhodamine 123 uptake relative to the negative control determined by monitoring 
intracellular fluorescence. Taxol, a microtubule stabilizing agent that exhibits 
neuroprotective effects both in vitro and in vivo, is hampered as a CNS therapeutic 
because it is a known P-gp substrate (26). Used as a positive control, Taxol significantly 
increased rhodamine 123 uptake in bovine brain microvessel endothelial cells 
(BBMECs), while addition of A4 had no effect on uptake even up to 50 µM, suggesting 
A4 is not likely a substrate for P-gp (Fig. 5a).  
The ability to partition across the blood-brain barrier is an essential property of 
drugs that are designed to produce beneficial effects on neuronal cells of the central 
nervous system (CNS). Transport across primary cultures of BBMECs in vitro often 
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correlates well with the BBB permeability of a compound in vivo (27). In the side-by-side 
diffusion chamber, A4 exhibited time-dependent linear transport across BBMECs for up 
to 90 min in the receiving chamber (Fig.5b).  The concentration of A4 at 90 min in the 
receiving chamber (1.2 µM) was 200-fold greater than the concentration necessary (5 
nM) for 50% neuroprotection from Aβ-induced toxicity. These data offer preliminary 
indication that pharmacologically active amounts of A4 might penetrate the BBB and 
result in the presence of drug in brain tissue. 
 
Discussion 
 
 Intracellular protein aggregation is a defining pathology of numerous 
neurodegenerative disorders, including Huntington’s disease, PD, and AD (1). In AD, tau 
aggregation results from its hyperphosphorylation and subsequent disassociation from 
microtubules to form filamentous aggregates that polymerize into NFTs. It has been 
proposed that increased Aβ levels lead to alterations in intracellular kinase and 
phosphatase activity, which ultimately results in pathogenic hyperphosphorylation. 
Therapeutic strategies directed at numerous individual pharmacological targets in this 
pathway have been tested as potential treatments for AD. Strategies designed to reduce 
the levels of Aβ peptides in the brain include inhibition of proteolytic enzymes that form 
Aβ, prevention of Aβ oligomerization through metal chelators, and upregulation of 
proteases that normally degrade Aβ (28). Previous attempts to prevent tau aggregation 
have generally focused on the identification and inhibition of specific kinases involved in 
its abnormal phosphorylation. Microtubule-stabilizing agents such as Taxol may prevent 
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loss of the microtubule-stabilizing activity of tau and such agents have also exhibited 
neuroprotective activity against a variety of toxic insults (21).    
 The inducible nature of Hsps makes Hsp90 inhibition a unique and exciting 
strategy for the treatment of AD and other neurodegerative disorders in which protein 
aggregation is a major pathology. The direct mechanism responsible for the 
neuroprotective effects of Hsp90 inhibitors appears to be the upregulation of chaperones 
that can resolubilize these toxic aggregates. Dou et al suggest that Hsps can directly 
associate with tau proteins and prevent their misfolding and subsequent aggregation (6). 
The independent identification of a series of Hsp90 inhibitors that lower intracellular tau 
levels through induction of Hsps supports this hypothesis (29). Recently, tau was 
identified as a substrate for CHIP, and it was suggested that increased levels of Hsp70 
can shift the equilibrium towards formation of the CHIP/Hsp70/tau complex, resulting in 
rapid clearance of tau aggregates via the ubiquitin-proteasome pathway (30).  Therefore, 
induction of Hsp70 appears to play a major role in the removal of tau aggregates. More 
recently, a high-throughput assay designed to identify compounds that block JNK-
dependent apoptosis identified AEG3482 as an Hsp90 inhbitor with potential 
neuroprotective properties (31). The data suggest that JNK inhibition is a downstream 
result of Hsp90 inhibition and subsequent Hsp70 induction. Hsp70 is known to bind JNK 
and disrupt substrate interactions, thereby, inhibiting its kinase activity. Taken together, 
this evidence strongly suggests that increased Hsp70 levels are a key factor in the 
neuroprotective effects of A4 and other Hsp90 inhibitors.  
 The development of Hsp90 inhibitors as chemotherapeutics has focused almost 
entirely on their use as anticancer agents. Numerous Hsp90 client proteins are essential 
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for the growth and proliferation of cancer cells, resulting in cytotoxic effects. This 
detrimental property has been a key reason behind their lack of development as 
neuroprotective agents. In contrast to GA and other N-terminal inhibitors, A4 is the first 
compound reported that induces Hsp70 and provides complete protection against Aβ-
induced toxicity at non-cytotoxic concentrations. In fact, no toxicity was observed in our 
assays even at 20,000 X the EC50 (100 µM) in non-neuronal cells, a concentration at 
which GA is severely toxic. In addition, A4 increases Hsp90 levels at concentrations ~ 
200-fold less than those required for client protein degradation. This provides a large 
therapeutic window for treatment of several disorders in which chaperones provide a 
protective effect. These attributes make A4 an ideal lead compound for development as a 
novel chemotherapeutic that might slow progression of neurodegeneration in AD. 
Current studies are underway to evaluate this new lead compound in animal models as 
well as in cells transfected with mutant tau to elicit the effects of p-tau aggregation. 
A major obstacle for any drug whose site of action is within the CNS is the ability 
to penetrate the BBB. In general, only small molecules with high lipid solublility and 
relatively low molecular weight (~400-500 Da) are able to cross the BBB (32). To date, 
few brain disorders have responded to small molecule therapies and many, including AD, 
PD, and Huntington’s disease have not been successfully targeted (33,34).  The time-
dependent linear transport of A4 across BBMECs in vitro suggests that significant 
concentrations of the drug will be available to the CNS in vivo. Within 15 min, the 
concentration of A4 present in the abluminal chamber was enough to provide full 
neuroprotective effects as demonstrated in vitro, suggesting that in vivo neuroprotection 
could be fast-acting.  
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 In summary, we have further characterized a novel C-terminal Hsp90 inhibitor, 
A4, as a potent neuroprotective agent for the treatment of AD. The protection against Aβ-
induced toxicity exhibited by A4 at concentrations that are non-cytotoxic provides a large 
therapeutic window and establishes it as the first Hsp90 inhibitor to manifest this unique 
property. In addition, the biological activities of A4 suggest that C-terminal inhibitors of 
Hsp90 work through a different mechanism than the known N-terminal inhibitors and 
may exhibit other unique pharmacological profiles that will be useful for the treatment of 
other neurodegenerative disorders. 
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Scheme 1. Synthesis of A4. 
 
 
 
 
 160 
Figure 2. 
%
 N
e
u
ro
n
a
l 
P
ro
te
c
ti
o
n
0
20
40
60
80
100
C
on
tro
l
A
4 
(1
00
nM
)
A
4 
(0
.1
 n
M
)
A
4 
(0
.5
 n
M
)
A
4 
(1
 n
M
)
A
4 
(5
 n
M
)
A
4 
(1
0 
nM
)
A
4 
(2
0 
nM
)
A
4 
(5
0 
nM
)
A
4 
(1
00
 n
M
)
*
*
**
**
**
A
4 
(0
.0
1 
nM
)
 
 
 
 
 
 
 
 
 
 
 
 
 161 
 
Figure 3. 
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Figure 5. 
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Figure Legends 
 
Figure 1. Structures of Hsp90 Inhibitors. Structures of the N-terminal Hsp90 
inhibitors, GA and 17-AAG, and the C-terminal inhibitors, novobiocin and A4. 
 
Figure 2. Dose-dependent A4 protection against Aβ25-35 toxicity. Neuronal cells were 
treated with vehicle only (clear), A4 (100 nM, gray), or A4 + Aβ (10 µM, black). The 
indicated concentrations of A4 were added 2 h before Aβ. Cell viability was determined 
48 h later as described in the methods section. *p<0.05 and **p<0.01, for Aβ alone vs. 
A4 + Aβ. Data represent mean survival ± SE for three separate experiments with ~1500 
cells per treatment condition. Aβ (10 µM) alone was used as 0% survival and DMSO 
control was used as 100% protection. 
 
Figure 3. A4 upregulates Hsp70 in neuronal cells. (a) Primary cortical neurons were 
incubated with GA or A4 for 48 h and probed for Hsp70 and actin (control). (b) The ratio 
between Hsp70 to actin was determined for each treatment as described (41). The first 
and second bars of each A4 treatment represent 24 and 48 h, respectively. *p<0.05 
compared to DMSO control. Each bar represents the average of four separate 
experiments. 
 
Figure 4. Anti-proliferative and toxic effects of A4 and GA. MCF-7 (a) or SkBr3 (b) 
cells were incubated with A4 (closed circles) or GA (open circles) at varying 
concentrations. Viable cells were quantitated using the MTS/PMS assay as described in 
the methods section. Values represent the mean ± SE for one representative experiment 
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performed in triplicate. Assays were replicated three times and the IC50 of GA correlated 
well with previously published values (MCF-7=133 ± 2 and SkBr3=18 ± 5 nM). In (c), 
neuronal cells were treated with DMSO (open bar), A4, or GA at the indicated 
concentrations, and cell viability was determined 24 h later as described in methods 
sections. The data represent the mean percentage ± SE of surviving neurons for three 
separate experiments. *p<0.05 for control versus GA, and **p<0.001 for control verus 
GA. 
 
Figure 5. Efflux and Transport of A4 across BBMECs. (a) BBMECs were grown to 
confluency and incubated with Rhodamine 123 (5 µM) alone or A4 (indicated 
concentrations) + Rhodamine 123 as described in methods section. Taxol (10 µM) was 
used as a positive P-gp substrate. (b) BBMECs were grown to confluency on 
polycarbonate membranes and A4 (10 µM) was added to the donor chamber. Aliquots 
from the receiver chamber were taken at the noted time points and analyzed by RP-HPLC 
for A4 permeation across the cell layer. 
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Appendix 2:  Structures of Paclitaxel Derivatives
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